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Abbrevations 
5’-Aza 5-Azacytidine 
Ad adjust to exact volume  
ATP adenosine triphosphate 
APS Ammonium persulfate 
BES N,N-bis (2-Hydroxyethyl)-2-aminoethanesulfonic acid 
BBS Borate Buffered saline 
bp base pair 
BS bisulfate solution 
BSA bovine serum albumin 
CA virus capsid  
CCR5 chemokine receptor type 5 
CD4 glycoprotein, expressed on the surface of T lymphocytes 
cDNA complementary DNA 
CMV cytomegalo virus 
CpG cytosine and guanine dinucleotide separated by one phosphate 
cPPT central polypurine tract 
dATP Deoxyadenosine triphosphate 
dCTP Deoxycytidine triphosphate 
dGTP Deoxyguanosine triphosphate 
DMEM Dulbecco's Modified Eagle Medium 
DMSO dimethyl sulfoxide 
Dnmt3a De-novo Methyltransferase 3a 
Dnmt3b De-novo Methyltransferase 3b 
dNTPs desoxynucleotide mix 
dTTP Deoxythymidine triphosphate 
E.coli   Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
eGFP enhanced green fluorescent protein 
env envelope gene of wildtype HIV 
ES cell embryonic stem cell 
FACS fluorescence activated cell sorting 
FBS fetal bovine serum 
gag retroviral gag gene encoding group specific antigens  
gp120 envelope glycoprotein gp120 of wildtype HIV 
gp41 envelope glycoprotein gp41 of wildtype HIV 
gDNA genomic DNA 
H&E hematoxylin and eosin staining 
HBSS Hanks' Balanced Salt Solution 
HEK293T human embryonic kidney 293 cells expressing large T antigen 
from simian virus 40  
HIV human immunodeficiency virus 
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HRP horse radish peroxidase 
HSCs haematopietic stem cells 
ICM inner cell mass 
IMDM  Iscove's Modified Dulbecco's Medium 
iPS  induced pluripotent stem cell 
kb kilo base 
kDa kilo Dalton 
KH2PO4 Monopotassium phosphate 
LB+ Luria-Bertani medium with glucose 
LTR long terminal repeat 
LVs lentiviral vectors 
MA matrix proteins 
MeCP2 methyl-CpG-binding protein 2 
mRNA messenger ribonucleic acid 
MLV murine leukemia viruses 
PAGE polyacrylamide gel electrophoresis  
PB primer binding site 
PBS phosphate buffered Saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PGK phosphoglycerate kinase  
PIC preintegration complex 
pol retroviral pol gene encoding polymerases 
ψ (Psi) packaging signal sequences of retroviruses 
RVs simple retroviral vectors 
rev rev gene of wildtype HIV, regulator of expression  
rpm revolutions per minute 
RRE rev response element 
RSV Rous sarcoma virus 
RT room temperature 
SA splice acceptor  
SD splice donor 
SDS Sodium dodecyl sulfate 
SFCA surfactant-free cellulose acetate 
SI subzonal injection 
SIN self inactivating 
Taq Thermophilus aquaticus 
TAR trans-activation response element, binding site for the Tat protein 
tat tat gene of wildtype HIV, trans-activator of transcription 
TBE Tris-borate-EDTA buffer 
TBS Tris-buffered saline 
TBS-T Tris-buffered saline supplemented with Tween-20 
TEMED N, N, N’, N’-tetramethylethylenediamine 
Tris Tris-hydroxyethyl aminomethan 
TSA Trichostatin A 
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UV ultraviolet 
vif accessory genes of wildtype HIV 
vpr accessory genes of wildtype HIV 
vpu accessory genes of wildtype HIV 
VSV.G glycoprotein of vesicular stomatitis virus 
WPRE post-transcriptional regulator element of Woodchuck hepatitis 
virus 
E.coli XL-1blue Escherichia coli strain, used for transformation of plasmids 
(prepared as competent cells) 
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1. Introduction 
1.1. Retroviruses 
Retroviruses belong to the Retroviridae family (Coffin, 1990; Coffin, 1992; Russell & 
Miller, 1996), which comprises various enveloped RNA viruses. The viral particles have a 
diameter of 80-100nm (Coffin, 1992). One characteristic of retroviruses is their capability 
to integrate into the genome of the host cells after reverse transcription of their viral RNA 
(Vogt, 1997). Figure 1 shows a schematic illustration of a lentivirus particle of 
Retroviridae family, i.e. the human immunodeficiency virus (HIV). The outer envelope 
membrane consists of a lipid bilayer with two transmembrane (TM) proteins (glycoprotein 
120 (gp120) and 41 (gp41)) that are anchored on the surface of the envelope membrane 
(Figure 1) (Coffin, 1992; Vogt, 1997). Within the viral particle, matrix proteins (MA) are 
connected to the inside of the envelope membrane (Figure 1). Within the MA, a conical 
viral capsid (CA) contains two identical linear single-stranded RNAs with 7-12 kb in size 
(Vogt, 1997) and several viral enzymes including reverse transcriptase, integrase and 
proteinase (Figure 1) (Coffin, 1992).  
 
Figure 1: Schematic illustration of a lentivirus particle, human immunodeficiency virus (HIV-1). HIV-
1 belongs to retroviruses. Graphic is modified from the cover of Journal of the American Biological Safety 
Association (Volume 12, Number 2, 2007, http://www.absa.org/abj/abj/ABJ2007v12n2.pdf) 
All retroviruses carry three essential genes gag, pol and env (Figure 2, see also Figure 6). 
The gag genes encode domains for synthesis of MA, CA and structural proteins; the pol 
genes encode for the essential enzymes including reverse transcriptase, integrase and 
proteinase; and the env genes contain domains for surface and transmembrane components 
of viral surface proteins, i.e. glycoproteins (Figure 2).  
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The viral genome is flanked by regulatory cis-active sequences (Figure 2) that contain 
essential elements responsible for reverse transcription and also for the integration (Kao et 
al, 1987; Starcich et al, 1985). The R-region (R = redundant) on 5’ and 3’ ends of the viral 
genome contains identical sequences and is flanked with a cap structure at the 5’end 
(Modrow et al, 2010). Upstream of the U5 (U = unique) element a sequence is located that 
is mainly responsible for the integration of the provirus into the host cell chromosome. 
Downstream of U5 element exits the primer binding site (PB) to which a complementary 
cellular tRNA can bind. A splice donor (SD) downstream of PB is responsible for the 
production of spliced mRNA (Starcich et al, 1985). Following to SD, the packaging signal 
sequences (abbreviated as ) are required for encapsidation of viral RNA (Clever et al, 
2000). A polypurine tract (abbreviated as PP) on 3’ end of gag/pol/env genes is important 
for the initiation of synthesis of double-stranded DNA by reverse transcription. During the 
viral reverse transcription, U3-region will be duplicated and copied on to 5’ ends. This 
results in the formation of long terminal repeat (LTRs) consisting of U3-R-U5 on both 
ends of provirus double-stranded DNA. Additionally, the U3-region contains promoter and 
cis-acting control elements where cellular proteins bind to regulate the gene transcription 
(Modrow et al, 2010).  
 
Figure 2: Viral RNA of retroviruses. Image is modified from Modrow et al, 2010 (Modrow et al, 2010) 
 
1.2. Life cycle of retroviruses 
To enter the host cell, the retroviral surface glycoprotein (i.e. gp120 in case of HIV) binds 
in the first step to specific plasma membrane receptors (i.e. CD4 receptor) (Figure 3). After 
attachment to the cells, TM glycoproteins mediate the fusion with the cell membrane and 
the uncoating of viral particles. Afterwards, the viral RNA and essential enzymes including 
reverse transcriptase are released into the cytoplasm of host cells. The reverse transcription, 
which takes place in the cytoplasm by the viral reverse transcriptase, leads to the 
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generation of double-stranded DNA from viral RNA. This double-stranded provirus DNA 
is further transported into the nucleus and inserted into the host cell’s chromosome by the 
viral integrase. This results in an integrated provirus. The provirus is further transcribed by 
cellular RNA polymerase II and single-, multiple-spliced mRNAs and also the full-length 
virion RNA genome are generated. Viral mRNAs are translated by the cellular ribosome in 
the cytoplasm resulting in formation of ENV, Gag and Gag-Pol polyproteins. These virion 
proteins and the virion RNA genome are assembled at the cell periphery and the plasma 
membrane. Finally, all components of the virus including envelope, capsid and matrix 
form a complex virus (virion), bud through the plasma membrane and are released from 
the host cells. 
 
Figure 3: Life cycle of retroviruses. Modified after Pfeifer and Verma (2001) (Pfeifer & Verma, 2001a). 
 
1.3. Simple and complex retroviruses 
Retroviruses can be divided into two subgroups according to their genome: simple 
retroviruses and complex retroviruses (Coffin, 1992; Vogt, 1997). The simple retroviruses 
carry three major coding regions for viral proteins as already abbreviated as gag, pol and 
env (see also Figure 2). In addition to the three major coding regions, complex retroviruses 
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contain regulatory and accessory genes derived from multiple spliced mRNA (Vogt, 1997). 
For example, HIV that belongs to genus Lentivirus (complex retrovirus) has additional 
regulatory genes including tat (trans-activator of transcription) and rev (regulator of 
expression) and also accessory genes including vif, vpr, vpu, nef (see Figure 5). The Tat 
protein mediates the trans-active response (TAR) (Jones, 1997; Modrow et al, 2010) by 
binding to the TAR element that is essential for trans-activation of the viral promoter and 
virus replication (Kulinski et al, 2003). The Rev protein of HIV is responsible for post-
transcriptional gene regulation during the replication cycle (Modrow et al, 2010; Pollard & 
Malim, 1998) by binding of Rev proteins to the RRE (rev response element). This enables 
an export of full-length viral mRNAs or multiple-spliced viral mRNA from the nucleus 
into the cytoplasm (Fischer et al, 1994). The Vif protein is a component of nuclear protein 
complexes of infectious viral particles that are necessary for HIV-1 replication in vivo 
(Marin et al, 2003; Modrow et al, 2010). The Vpr protein contributes to the transport of the 
pre-integration complex (PIC), which contains all necessary components for viral 
integration, into the nucleus. The Vpu protein enhances virus particle secretion (Geraghty 
et al, 1994; Schubert et al, 1996b) and enables more efficient shedding of viral particles 
(Schubert et al, 1996a). The Nef protein also increases the viral infectivity (Hirsch & 
Curran, 1996).  
Besides these structural differences, the main difference between simple and complex 
viruses is their infection mode: The complex retroviruses (e.g. lentivirus, HIV-1) are able 
to infect dividing as well as nondividing cells (Figure 4 left) (Gallay et al, 1997; Lewis & 
Emerman, 1994) whereas the simple retroviruses (e.g. gammaretroviruses, MLV) are 
unable to infect the nondividing cells (Figure 4 right) (Lewis & Emerman, 1994; 
Yamashita & Emerman, 2006). In an early study it was suggested that the capsid protein 
plays an important role for the difference between HIV and MLV in their ability to 
transduce nondividing cells (Yamashita & Emerman, 2004). During fusion with the 
cellular membrane, HIV-1 capsid degrades quite early (Fassati, 2006), which leads to low 
abundance of CA. The minimal residual of capsid shell favors the cellular transport of PIC 
(Yamashita & Emerman, 2004). In contrast, MLV PIC contains a capsid shell until the 
nuclear entry (Fassati, 2006) that blocks the cellular transport of PIC (Yamashita & 
Emerman, 2004). Therefore, MLV provirus can not enter the nuclear membrane through 
nuclear pores. The provirus of MLV can only access the host cell chromosome during the 
cell mitosis when there is brief dissolve of nuclear membrane (Lewis & Emerman, 1994).  
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Figure 4: Schematic representation of integration progress of complex retroviruses (e.g. HIV-1)(left) 
and simple retroviruses (e.g. MLV)(right).  
 
1.4. Retroviral and Lentiviral vectors 
For using retro- or lentiviral vectors as a gene vehicle for transfer of transgenes into host 
cells leading to stable transgene expression, different systems were already established that 
are all based on the same principle. For the establishment of the viral vector system, the 
first step is to identify which viral genes are responsible for pathogenesis, replication and 
production of infectious particles. For safety propose, all pathogenesis-related genes were 
deleted from the viral genome. The essential viral genes for virus production were 
separated into two systems: the viral plasmids and the packaging constructs (Pfeifer & 
Verma, 2001a).  
The viral plasmids contain the transgene cassette and cis-active sequences that are 
necessary for encapsidation of the viral vector genome and for viral transduction of the 
target cells. The packaging constructs contain viral sequences encoding genes for viral 
proteins essential for packaging of the vector genome and replication. For virus production, 
viral plasmids and packaging constructs are co-transfected into packaging or helper cells 
(e.g. HEK 293T cells). Afterwards, the recombinant viral particles are released from the 
packaging cells. These viruses are infectious but replication defective. Mostly, lentiviral 
vectors (LVs) generated in this way are based on HIV-1’s sequence (Figure 5) and 
gammaretroviral vectors (RVs) on MLV (Figure 6). 
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Figure 5: Schematic representation of lentiviral vector (LV) and packaging constructs derived from 
wildtype HIV-1 genome. Black inverse triangle indicates the deletion of LTR’s promoter/enhancer at 3’ 
LTR. 
In detail, the wildtype HIV-1 accessory genes vif, vpr, vpu and nef (Figure 5) are related to 
viral pathogenesis. They are important for the viral life cycles in vivo but they are not 
essential for viral replication in vitro (Delenda, 2004; Kim et al, 1998; Zufferey et al, 1998). 
Therefore, to reduce the infectious risk of LVs removal of these viral elements from HIV 
genome led to the generation of lentiviral plasmid just containing the cis-active sequences 
and packaging signal sequences  of HIV-1 (Dull et al, 1998). Furthermore, it was shown 
that deletion of these elements does not compromise gene transduction (Zufferey et al, 
1997). Furthermore, components of the 3’ LTR were deleted (marked with black triangle 
in Figure 5). As parts of the 3’ LTR are transferred to the 5’ LTR during the process of 
reverse transcription (please refer to 1.1. or see below for details) this deletion leads to loss 
of promoter activity in the 5’ LTR. Thus, an internal promoter was inserted in the lentiviral 
plasmid that can be ubiquitous and also tissue specific. 
Besides the lentiviral plasmid several packaging plasmids encoding necessary genes have 
to be co-transfected in the producer cell line. The plasmid containing viral gag-pol cDNA 
provides the production of the essential enzymes and virion proteins. The regulatory 
protein Rev, encoded on a separate construct, interacts with RRE and enables production 
of high-titer viruses (Dull et al, 1998) as Rev enhance the nuclear export of unspliced gag-
pol mRNA and viral vector RNA (Delenda, 2004). The native envelope gene env of HIV-1 
restricts the infection of only cells that express CD4 protein and coreceptors (Berger et al, 
1999; Wyatt & Sodroski, 1998). In order to increase the host cell spectrum, the env has 
been replaced with heterologous viral envelope proteins (pseudotyping), e. g. with the 
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glycoprotein of vesicular stomatitis virus (VSV.G) that is encoded on a third packaging 
plasmid (Naldini et al, 1996; Reiser et al, 1996). Besides the broader host tropism of 
VSV.G enveloped LVs, this envelope enables virus purification by ultracentrifugation. 
Furthermore, it facilitates production of viral vectors with higher titers and with increased 
resistance against freezing and thawing (Lever et al, 2004).  
The retroviral genome of MLV is also separated into two groups: the retroviral plasmid 
and the packaging constructs (Figure 6). In detail, the viral plasmid contains the transgene 
cassettes that are under the control of the prototypic LTR promoter (Figure 6A) or internal 
promoter (Figure 6B). The essential virion and envelope proteins for packaging are divided 
into two expressing plasmids including gag-pol gene encoding virion proteins and the gene 
encoding for the wildtype ecotropic envelope proteins (Figure 6, right). In addition, RVs 
can also be pseudotyped with the VSV.G envelope.  
 
Figure 6: Schematic representation of retroviral vectors (RV) and packaging constructs derived from 
wildtype MLV genome with wildtype LTR-promoter (A) or with internal promoter (B). Black inverse 
triangle indicates the deletion of LTR’s promoter/enhancer at 3’ LTR. 
During the viral reverse transcription in host cells, the 3’ U3 and 5’ U5 region of viral 
RNA are duplicated, which results in formation of LTR consisting of U3-R-U5 with the 
U3 region containing viral promoter and enhancer elements. Thus, the 5’ LTR has 
promoter activity and regulates the transcriptional initiation of cellular RNA polymerase II 
(Figure 7 right). As retroviral or lentiviral vectors integrate randomly into host genome, 
therefore they may cause an insertional activation of cellular oncogenes (Miyoshi et al, 
1998). This reveals a biosafety problem when prototypic LTR-promoters are included in 
viral vectors. Therefore, the U3 promoter/enhancer elements of 3’ LTR are deleted in the 
lenti- or retroviral plasmids (black triangle in viral vectors in Figure 5, 6B and 7). During 
reverse transcription, these deleted elements are no longer transferred into 5’ LTR, which 
prevents the transcriptional activity of 5’ LTR in the integrated provirus. The viral vectors 
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carrying deleted U3 promoter are termed self-inactivating (SIN) vectors including SIN-
RVs and SIN-LVs as they inactivate promoter activity during their own reverse 
transcription of RNA (Kim et al, 1998; Miyoshi et al, 1998; Yu et al, 1986; Zufferey et al, 
1998). SIN vectors carry an internal promoter to drive transgene expression. Moreover, in 
SIN vectors the transcriptional interference between LTR promoter and the internal 
promoter is prevented (Zufferey et al, 1998).  
 
Figure 7: Schematic illustration of viral vectors with wildtype LTR promoter (left) and SIN vectors 
with internal promoter (right). . Black inverse triangle indicates the deletion of LTR’s promoter/enhancer 
at 3’ LTR. 
In addition, the efficiency of gene transfer can be increased by inserting a regulatory 
sequence into the viral plasmid. For example, a central polypurine tract (cPPT) has been 
suggested to promote nuclear translocation of the PIC (Van Maele et al, 2003; Zennou et al, 
2000). The insertion of a post-transcriptional regulatory element of Woodchuck hepatitis 
virus (WPRE) led to a substantial raise of expression and stability of the transgene 
(Zufferey et al, 1999). 
 
1.5. Pluripotent stem cells: embryonic stem cells and induced pluripotent stem cells 
Embryonic stem (ES) cells are derived from the primitive ectoderm of the inner cell mass 
of blastocysts (Figure 8) (Evans & Kaufman, 1981; Nagy et al, 1993). They are 
characterized by their self-renewal capability and their pluripotency, i.e. they can develop 
into the primary germ layers (ectoderm, endoderm, and mesoderm) (Tanaka et al, 2009; 
Wobus & Boheler, 2005). Because of their capacity to differentiate into all cell types of the 
adult body (Figure 8), ES cell-based therapies have been proposed for regenerative 
medicine and tissue replacement (Wobus & Boheler, 2005). Moreover, the isolation of ES 
cells from human blastocysts was a breakthrough for a potential therapeutic use of ES cells. 
In previous studies, various cell types derived from murine or human ES cells have been 
identified including neurons (Carpenter et al, 2001; Li et al, 1998), pancreatic β-cells 
(Assady et al, 2001; Soria et al, 2000), cardiomyocytes (Kaufman et al, 2001; Klug et al, 
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1996) and endothelial cells (Levenberg et al, 2002; Quinn et al, 2000). Thus, in the last 
decade, these ES cells have been provided a potential tool for future regenerative medicine 
(Keller, 2005; Wobus & Boheler, 2005). So far, retinal pigment epithelia derived from 
human ES cells has been already applied in first clinical trial for Stargardt’s disease and 
macular degeneration (Schwartz et al, 2012).  
 
Figure 8: Schematic illustration for development pluripotent embryonic stem cells. (Modified from 
http://www.stemcellresearchfoundation.org/WhatsNew/Pluripotent.htm) 
However, there are still ethic disputes about the usage of human ES cells. To avert from 
ethic controversies, Yamanaka and coworkers have successfully developed a method for 
conversion of somatic cells into embryonic stem like-cells named induced pluripotent stem 
(iPS) cells by using four transcriptional factors (Figure 9) (Takahashi et al, 2007a; 
Takahashi & Yamanaka, 2006). Since then, a number of further reports demonstrated the 
successful generation of iPS cells using different approaches (Li et al, 2009; Warren et al, 
2010; Zhou et al, 2009). A recent report also shows the possibility to generate iPS by using 
only one transcription factor, i. e. Oct4 (Kim et al, 2009). Importantly, iPS cells are 
pluripotent like ES cells (Takahashi et al, 2007b) as they develop into the three germ layers 
involving all cell types of the adult body (Takahashi et al, 2007b). Furthermore, the 
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generation of patient-derived iPS cells has been proposed a possible solution to avoid 
immune responses after transplantation of ES cell-derived tissues (Maehr et al, 2009; 
Soldner et al, 2009). Therefore, iPS cells have been proposed as alternative cell sources for 
future cell replacement therapies or application in regenerative medicine instead of using 
ES cells (Robinton & Daley, 2012; Yamanaka & Blau, 2010).  
 
Figure 9: Schematic drawing of the generation of induced pluripotent stem (iPS) cells. Adult somatic 
cells are transduced with retroviruses encoding for four pluripotency factors (SOX2, KLF4, c-MYC and 
OCT4), leading to formation of iPS cells. Fully reprogrammed iPS cells have similar properties as ES cells. 
Schematic presentation is modified from Yamanaka and Blau, 2010 (Yamanaka & Blau, 2010). 
 
1.6. Epigenetic regulation of LVs and RVs in ES cells 
An early study showed that the injection of MLVs in mouse embryos led to transgene 
expression in newborn mice after transferring MLV-injected embryos in foster animals 
(Jaenisch et al, 1975). However, other studies revealed a transcriptional repression (gene 
silencing) of the transgene during the early mouse embryo development of MLV derived 
RVs (Jaenisch et al, 1982; Jahner et al, 1982; Speers et al, 1980). A de nova methylation of 
CpG nucleotides within proviruses has been proposed as a major cause of the 
transcriptional silencing (Challita & Kohn, 1994; Cherry et al, 2000; Jahner et al, 1982; 
Laker et al, 1998). DNA methyltransferases 3a and 3b (Dnmt3a and Dnmt3b) are probably 
responsible for this de novo methylation (Lei et al, 1996; Okano et al, 1999). In detail, 
methylated DNA can be targeted by the methyl-CpG-binding protein 2 (MeCP2) which is 
associated with transcriptional repressor complexes including histone methyltransferase as 
well as histone deacetylase (HDACs) which facilitate the remodeling of chromatin and 
repression of transcription (Bird & Wolffe, 1999; Fuks et al, 2003; Jones & Baylin, 2002; 
Lorincz et al, 2000). The HDACs in turn can remove acetyl groups from histones leading 
to silent chromatin structures by histone modifications (Jones et al, 1998; Nan et al, 1998).  
It has also been reported that high methylation levels of wildtype HIV-1 led to 
transcriptional inactivation of viral DNA in mammals (Bednarik et al, 1990). Silencing of 
Introduction 
19 
 
LVs-mediated transgene has been first observed in hematopoietic stem cells (May et al, 
2000). Silencing occurred mostly when using wildtype HIV-1 LTR promoter whereas only 
half of the integration sites were silenced when SIN-LVs were applied lacking the wildtype 
LTR promoter activity (Pannell et al, 2000). Previous studies demonstrated that SIN-LVs 
can be used for efficient gene transfer in ES cells and lead to expression of the transgene 
after differentiation (Hamaguchi et al, 2000; Pannell et al, 2000; Pfeifer et al, 2002). 
However, not all integration sites of lentiviruses lead to proper expression in transgenic 
animals indicating that transgene expression is still regulated by the cellular silencing 
machinery (Hofmann et al, 2006; Lois et al, 2002; Pfeifer et al, 2002). Furthermore, de 
nova methylase independent silencing of retroviral and lentiviral vectors has also been 
reported in ES cells, which suggests an important role of the modification of the chromatin 
structure and histones on retrovirus silencing (Pannell et al, 2000; Yao et al, 2004). 
 
1.7. Risks of pluripotent stem cells 
As mentioned before, several studies showed that murine or human ES cells can develop 
into different cell types like neurons, pancreatic β-cells and cardiomyocytes. In addition, 
iPS cell-derived neurons (Wernig et al, 2008) and cardiomyocytes (Mauritz et al, 2008) 
were also successfully generated. Thus, in the last decade, these pluripotent stem cells 
including ES and iPS cells have been provided a potential tool for future regenerative 
medicine (Keller, 2005; Wobus & Boheler, 2005) 
However, the usages of pluripotent stem cells for gene therapies carry a potential risk of 
tumor (teratoma) formation in vivo if the transplanted cells are contaminated by residual 
undifferentiated cells (Bjorklund et al, 2002; Blum & Benvenisty, 2008; Nussbaum et al, 
2007; Wakitani et al, 2003). Hence, removing the undifferentiated cells from differentiated 
cell populations has been considered as an essential procedure. 
Up to now, the transfer of a suicide gene to potential risk cells has been established as a 
promising concept for tumor elimination in clinical trials (Portsmouth et al, 2007). One 
approach is based on the gene/prodrug combination herpes simplex virus thymidine kinase 
(HSV-TK) and ganciclovir (GCV) treatment. HSV-TK converts the prodrug GCV to a 
toxic metabolite leading to cell death. Importantly, the HSV-TK/GCV system has been 
widely used in several clinical trials e.g. for cancer therapy (Kubo et al, 2003; Sterman et 
al, 1998). Thus, one possibility to eliminate undifferentiated cells would be the 
implantation of a suicide gene, e.g. the mentioned TK cDNA and treatment of these cells 
Introduction 
20 
 
with GCV (Jung et al, 2007; Schuldiner et al, 2003). Indeed, several research groups 
already modified ES cells genetically in order to express HSV-TK (Goodwin et al, 2001; 
Jung et al, 2007; Naujok et al, 2010; Rong et al, 2012; Schuldiner et al, 2003). It has 
recently been shown that LV-mediated TK expression driven by the promoter of 
pluripotency gene in pluripotent stem cells might selectively ablate pluripotent stem cells. 
The use of LVs carrying TK cDNA did not alter the pluripotency and self-renewal capacity 
of the cells but made them sensitive to GCV (Cheng et al, 2012). 
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1.8. Aim of the work 
Previous studies reported silencing of transgenes in murine embryos (Jahner et al, 1982) 
and embryonic stem (ES) cells when using wildtype retroviral vectors (RVs) as well as 
wildtype lentiviral vectors (LVs) (Pannell et al, 2000). In the next generation of these viral 
vectors a self inactivating (SIN) mutation was inserted in the LTR leading to loss of the 
wildtype promoter activity. In these vectors of retro- (SIN-RV) or lentiviral (SIN-LV) 
origin an additional internal promoter was inserted. Comparing the viral vectors showed 
that SIN-LVs resulted in more stable transgene expression as compared to wildtype RVs 
(Ikawa et al, 2003; Lois et al, 2002; Pfeifer et al, 2002). For SIN-RVs and SIN-LVs an 
equal potency has been reported in hematopoietic cells (Schambach et al, 2006a). However, 
no extensive studies have been done so far comparing SIN-LVs and SIN-RVs in murine 
ES cells or in transgenic mice. Within the first part of the present study it was therefore 
investigated how SIN-LVs and SIN-RVs are epigenetically regulated in murine ES cells. 
Besides the in vitro measurements transgenic mice were generated by applying subzonal 
injection of SIN-LVs and SIN-RVs to analyze the epigenetic regulation in vivo and to 
compare the efficiency when using the two different SIN viral vectors. 
 
The second part of the present work focuses on the specific elimination of pluripotent stem 
cells for possible applications in regenerative medicine. Undifferentiated stem cells pose a 
great risk for the development of tumors after transplantation. Thus, this work aimed to 
remove such potential teratoma-forming cells by using a combination of the suicide gene 
thymidine-kinase that originally derives from Herpes simplex virus (HSV-TK) and 
treatment with the prodrug ganciclovir (GCV). HSV-TK converts GCV into a toxic 
metabolite leading to cell death. To genetically modify ES cells SIN-LVs were chosen 
carrying different promoters of pluripotency genes to drive TK expression. This in turn 
results in a specific elimination of only undifferentiated pluripotent stem cells upon GCV 
treatment. Besides the goal of maximal reduction of undifferentiated cells the study also 
focused on minimizing viral vector concentrations that had to be applied. Several in vitro 
analyses were performed using ES as well as iPS cells. Finally, genetically modified ES 
cells were applied in vivo in a mouse teratoma model and tumor formation was analyzed. 
The results are of interest for the potential use of pluripotent stem cells in regenerative 
medicine. 
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2. Materials and Methods 
All chemicals and solutions used in this study were purchased from companies Roth, 
Merck, Sigma and VWR with the highest purity and molecular biology grade. Cell culture 
dishes, pipettes and other disposable consumables for cell culture or molecular biology 
have been supplied by VWR or Sarstedt. For the preparation of solutions purified water 
was used (Water Purification System, arium®  611VF, Sartorius AG). 
 
Reagents 
Acrylamide, Roti-phorese®  Gel 30 (37.5:1) (Roth, Cat. No. 3029.1) 
Ampicillin sodium salt (Roth, Cat. No. HP62.2) 
CHIR 99021 (Axon Medchem, Cat. No. 1368) 
Collagenase B (Sigma-Aldrich, Cat. No. 11088807001) 
Coomassie dye, Coomassie brilliant blue (Merck, Cat. No. 1.15444.0025) 
Cytotoxicity Detection Kit (LDH) (Roche, Cat. No.11644793001) 
DNA Taq polymerase (Qbiogene, Cat. No. EPTQK109) 
Donkey serum (Jackson ImmunoResearch, Cat. No. 017-000-001) 
Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Cat. No. 61965, 31966 and 41966) 
Ethidium bromide 10 mg/ml (Carl Roth GmbH, Cat. No. 2218.1) 
FACS tube Polysterene 12x75mm (Sarstedt) 
Fetal calf serum (FCS) (Biochrom AG, Cat. No. S0115) 
Fox Chase SCID®  Beige mice (Charles River). 
Ganciclovir (Sigma-Aldrich, Cat. No. G2536-100MG) 
H2O (Sigma-Aldrich, Cat. No. W3500) 
Hanks' Balanced Salt Solution (HBSS) (Gibco, Cat. No. 14175-046) 
HEK 293T cells (ATCC, Cat. No. CRL-11268) 
Hoechst 33258 (Sigma-Aldrich, Cat. No. 861405-100MG) 
Hygromycin (Sigma-Aldrich, Cat. No. H3274-50MG) 
iQ Multiplex Powermix (Bio-Rad, Cat. No. 1725849) 
iQ SYBR Green Supermix (Bio-Rad, Cat. No. 170-8882) 
Iscove's Modified Dulbecco's Media (IMDM) (Gibco, Cat. No. 12440) 
Leukemia inhibitory factor (LIF) (Esgro, Cat. No. ESG1107) 
MEM, Non-Essential Amino Acids Solution (Gibco, Cat. No. 11140-050) 
mi-Pfu DNA polymerase (Metabion, Cat. No. mi-E6022) 
N,N-Bis(hydroxyethyl)-2-aminoethanesulfonic acid (BES) (Roth,Cat. No. 9134.2) 
NIH 3T3 cell (ATCC, Cat. No. CRL-1658) 
NucleoBond®  PC 500 EF maxi kit (MACHEREY-Nagel, Cat. No. 740550) 
PD 0325901 (Axon Medchem, Cat. No. 1408) 
Penicillin G/ Streptomycin (Biochrom AG, Cat. No. A2213) 
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PeqGOLD TriFast®  (Peqlab, Cat. No. 30-2020) 
Phenol/Chloroform/Isoamyl alcohol (Roth, Cat. No. A156.1) 
Poly-L-lysine solution (Sigma-Aldrich, Cat. No. P4832) 
Proteinase K (Roche, Cat. No .03115828001) 
Restriction enzymes (New England Biolabs (NEB)) 
Reverse transcriptase ELISA (Roche, Cat. No. 11468120910) 
ß-mercaptoethanol (Sigma-Aldrich,  Cat. No. M7522) 
Sucrose (Roth, Cat. No. 4621.1) 
T4 DNA ligase (Invitrogen, Cat. No. 15224-041) 
TA Cloning®  Kit (pCR® 2.1 TOPO) (Invitrogen, Cat. No. 45-0046) 
Transcriptor First Strand Synthesis Kit (Roche, Cat. No. 4896866) 
Trypsin (Gibco, Cat. No. 35400-027) 
E. coli XL-1 blue MRF (Stratagene, Cat. No. 200230) 
α32-P dCTP (Perkin Elmer ,Cat. No. NEG013Z001MC) 
 
Antibodies 
Primary antibodies: 
Mouse monoclonal α-actinin (Sigma-Aldrich, Cat. No. A7811-.2ML) 
Mouse monoclonal β-actin (Abcam, Cat. No. ab6276) 
Mouse monoclonal GFP (CLONTECH, Cat. No. 8371-1) 
Rabbit polyclonal Oct-3/4 (Santa Cruz, Cat. No. sc-9081) 
Goat polyclonal Thymidine kinase (Santa Cruz, Cat. No. sc-28037) 
Mouse monoclonal tubulin (Dianova, Cat. No. DLN-09992) 
 
Secondary antibodies: 
Goat polyclonal HRP (Jackson ImmunoResearch, Cat. No. 123-005-021) 
Mouse polyclonal HRP (Jackson ImmunoResearch, Cat. No. 115-035-146) 
Mouse polyclonal Dylight 649 (Jackson ImmunoResearch, Cat. No. 015-490-003) 
Rabbit polyclonal DyLight 549 (Jackson ImmunoResearch, Cat. No. 011-510-003) 
 
Equipment 
1,5ml screw-cap reaction tube (Sarstedt, Cat. No. 72.693.005) 
100 mm culture dishes (Sarstedt, Cat. No. 83.1802) 
100 mm Petri dish (Greiner, Cat. No. 663102) 
150 mm cell culture dishes (Falcon, Cat. No. 353025) 
250 ml tensid-free cellulose acetate bottle-top filter (SFCA)(0.45µm) (Nalgene, Cat. No. 
157-0045) 
6-well/24-well cell culture plate (Sarstedt, Cat. No. 83.1839/83.1836,) 
96-well plate reader SUNRISE RC/ST (Tecan)  
96-well plates with optical caps (Peske, Cat. No. 353072) 
Axio Observer.Z1 with Atopome system (Carl Zeiss) 
AxioCam MRC5 (Carl Zeiss). 
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AxioStart (Carl Zeiss) 
Cell scraper (Labomedic, Cat. No. 2015217) 
Centrifugation tubes (Beckman Coulter, Cat. No. 358126 and 326819) 
CL-1000 UV cross-linker (UVP)  
Gene Screen Plus Hybridization Transfer Membranes (PerkinElmer, Cat. No. 
NEF988001PK) 
Immobilon-P Transfer Membrane (PVDF)( Millipore, Cat. No. IPVH00010) 
Incubator HERAcell 150 (Thermo Scientific) 
Inverted cell culture microscope DMIL (Leica) 
iQ5 Real Time PCR System (Bio-Rad) 
P20, P200 and P1000 pipette (Gilson) 
Photometer/ Biophotometer (Eppendorf) 
Polysterene 12*75mm (Sarstedt) 
Reciprocating shaker 3006 (GFL) 
SW32Ti rotor (Beckman Coulter)  
SW55 rotor (Beckman Coulter) 
T1 Thermocycler (Biometra) 
Thermomixer (Eppendorf) 
Ultra-centrifuge Optima L-100 XP (Beckman Coulter) 
UV light transilluminator, GelDoc® XR (Geldoc) 
 
2.1. Lentiviral and retroviral vectors 
The original virus plasmids are derived from the lab of Inder Verma (The Salk Institute for 
Biological Studies, Laboratory of Genetics, La Jolla, CA, USA). The viral vector system 
for production of recombinant viruses consist of two major parts: the retroviral or lentiviral 
plasmids and the packaging construct (see also Figure 5, 6). The plasmids and the 
procedures of production are described in details below. 
 
2.1.1 Lentiviral plasmids and packaging constructs 
pRRL.SIN-18-PGKGFP: The self-inactivating lentiviral vectors (SIN-LVs) (Figure 5) 
contains the cis-active sequences of HIV-1 that are required for encapsidation of viral 
vector genome and for viral transduction of target cells, as well as the eGFP expression 
under the control of human phosphoglycerate kinase (PGK) promoter. The 5’ LTR 
contains enhancer elements and RSV promoter (Schambach et al, 2006a; Schambach et al, 
2006b) as a substitute of the wildtype U3-region to drive expression of the vector RNA in 
the packaging cells. The U3 promoter/enhancer sequences in the region of the 3’ LTR are 
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deleted leading to a SIN vectors (SIN as shown as black triangle in Figure 5) (Lois et al, 
2002; Pfeifer et al, 2002).  
pMDLg/pRRE: The construct pMDLg/pRRE (Figure 5) contains the gag and pol genes of 
HIV-1 driven by a Cytomegalovirus (CMV) promoter (Thomsen et al, 1984). Since the 
transcripts of the gag and pol genes contain cis-repressive sequences, they are only 
expressed by binding of rev to RRE (rev response element), which enables the export of 
the viral RNA from the nucleus (Dull et al, 1998). 
RSV-rev: The construct RSV-rev (Figure 5) expresses the rev gene driven by Rous 
sarcoma virus (RSV) promoter (Lois et al, 2002). 
pMD.G: The construct pMD.G (Figure 5) encodes a heterologous envelope protein from 
vesicular stomatitis virus (VSV.G) to pseudotype the viral vector. VSV.G is under the 
control of the CMV promoter (Lois et al, 2002).  
2.1.2 Retroviral plasmids and packaging constructs 
pSRS11-PGKGFP: SIN gammaretroviral vector (SIN-RV) contains the sequences of 
murine leukemia viruses (MLV) required for packaging, reverse transcription and 
integration, as well as the eGFP expression cassette under the control of human PGK 
promoter. The 5’ LTR of SIN-RV also contains enhancer elements and RSV promoter 
(Schambach et al, 2006a; Schambach et al, 2006b) as a substitute of the wildtype U3-
region to drive expression of the vector RNA in the packaging cells. The 
promoter/enhancer sequences in the U3 region of 3’ LTR were deleted to generate self-
inactivating vectors (Figure 6B) (Schambach et al, 2006a; Schambach et al, 2006b; Yu et 
al, 1986). 
pCLMFGGFP: gammaretroviral vector contains the cis-active sequences of MLV 
required for packaging, reverse transcription and integration, as well as the eGFP 
expression cassette under the control of wildtype LTR promoter (Naviaux et al, 1996) 
(Figure 6A). 
pCMV-gagpol: The construct pCMV-gagpol expresses the gag and pol genes of MLV 
driven by a CMV promoter (Figure 6).  
pMD.G: The construct pMD.G (Figure 5) encodes a heterologous envelope protein from 
vesicular stomatitis virus (VSV.G) to pseudotype the viral vector. VSV.G is under the 
control of the CMV promoter (Lois et al, 2002).  
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2.1.3. Virus-plasmid maxi preparation 
In order to obtain enough viral and packaging plasmid DNA for viral vector productions, 
plasmids were transformed into chemical (or heatshock) competent cells of strain E. coli 
XL-1 blue MRF (Stratagene). Cells were cultivated and plasmids were isolated by using an 
endotoxin-free Maxi kit (NucleoBond PC 500 EF). 
First, 50 ng plasmids were each incubated with competent cells on ice for 30 minutes. 
Afterwards, the cell suspension with plasmids was heat shocked at 42 ºC in a water bath 
for 45 seconds. Subsequently, 1 ml Luria-Bertani (LB
+
) medium without antibiotics was 
added and cells were incubated at 225 rpm shaking and 37ºC for 1 hour. After spinning 
down the cells at 3600 rpm for 5 minutes the supernatant was decanted. The cell pellet was 
resuspended in remaining medium and plated on LB plates containing ampicillin (100 
µg/ml). Plates were incubated at 37ºC for 16 hours or overnight. 
On the next day, single bacteria colonies were picked and inoculated in 5 ml LB
+
 medium 
supplemented with ampicillin (100 µg/ml). After 6 hours incubation at 37ºC with 225 rpm 
shaking, the medium with growing bacteria was transferred into 100 ml LB
+
 medium 
supplemented with ampicillin with 225 rpm shaking overnight. On the next day, bacteria 
were harvested by centrifugation (6K15 with 11150 rotor, Sigma) with 3600 rpm for 15 
minutes at 4 ºC. Subsequently, plasmids were isolated with an endotoxin-free Maxi kit 
NucleoBond PC 500 EF kit according to the manufacturer’s instructions (MACHEREY-
Nagel). 
 
LB
+ 
plate 
LB-Medium (Lennox) 20 g  
Glucose 1 g 
H2O Ad 1 l 
Agar-agar 15 g 
pH (with HCl) 7.2-7.5 
  
Autoclaved, poured into 100-mm petri 
dishes and stored at 4°C  
LB
+ 
Medium 
LB-Medium (Lennox) 20 g  
Glucose 1 g 
H2O Ad 1 l 
pH (with HCl) 7.2-7.5 
 
 
Autoclaved and stored at 4°C  
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2.1.4. Production of recombinant lentiviral and retroviral vectors 
For the production of recombinant lentiviral and retroviral vectors, HEK 293T (ATCC) 
cells were used as virus packaging cell. Twelve 150-mm cell culture dishes were coated 
with 8 ml poly-L-lysine solution per dish at room temperature (RT) for 15 minutes. After 
removing poly-L-lysine solution, 18 ml DMEM medium (DMEM supplemented with 10% 
fetal calf serum (FCS)) was applied in each dish. For plating virus packaging cells 150-mm 
cell culture dishes were used with HEK 293T cells of 100% confluency. Cells were 
washed with PBS, trypsinized with 2 ml trypsin and resuspended in 18 ml virus medium 
(20 ml at final volume). 2 ml of cell suspension was each transferred on poly-L-lysine 
coated dishes containing 18 ml medium. HEK 293T cells were then cultured at 37 °C, 10% 
CO2 overnight. 
 
Poly-L-lysine solution 
0.01% (w/v) poly-L-lysine 50 ml 
1xPBS 450 ml 
  
  
stored at 4°C   
 
DMEM medium 
DMEM (Cat. No. 61965) 
10% FCS 
100 U/ml Penicillin G 
100 μg/ml Streptomycin. 
stored at 4°C  
 
 
18 hours after cell split HEK 239T cells had a confluency of 40-60%. For transfection of 
the plasmids, transfection mixture was prepared by mixing the lentiviral or retroviral 
plasmids as well as packaging plasmids (Table 1). Afterwards, CaCl2 was added to the 
mixture and mixed by inverting. Finally, 2x BBS was added and mixed gently by inverting. 
After 15 minutes incubation at RT, the transfection mixture was applied dropwise to each 
cell culture dish with HEK cells. The dishes were swirled to distribute the mixture and 
cells were incubated at 37 °C, 3% CO2 overnight. 
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Table 1: Transfection mixture for co-transfection of HEK 293T cells (Pfeifer & Hofmann, 2009).  
*Different LVs and RVs were produced. They are detailed described in the Result part. 
 
 
1x PBS  
NaCl 40 g 
KCl 1 g 
Na2HPO4 7.2 g 
KH2PO4 1.2 g 
H2O Ad 5 l 
pH (with HCl) 7.4   
 
Autoclaved and stored at 4°C  
 
 
2x BBS 
N,N-bis(2-Hygroxyethyl)-
2-Amionethansulfon acids 
(BES) 
4.26 g 
NaCl 6.45 g 
Na2HPO4 0.085 g 
H2O Ad 400 ml 
pH (with HCl) 6.95   
Autoclaved and stored at 4°C  
Next day, the medium was replaced with fresh DMEM medium and incubated at 37 °C, 
10% CO2 overnight. If a viral vector carries a fluorescence-reporter gene, e.g. eGFP, more 
than 80% of the cells expressing fluorescence were observed showing high transfection 
efficiency. 
One day after medium change, the supernatants containing released recombinant viral 
particles in cell dishes were collected and 16 ml fresh virus medium per dish was added. 
The cells were again cultured at 37 °C, 10% CO2 overnight. Thereafter, the cell debris in 
the supernatants was removed through SFCA bottle-top filters. The filtered supernatants 
were further centrifuged by an ultracentrifuge with SW32Ti rotor at 61,700g at 17 °C for 2 
hours. Subsequently, the upper mediums were discarded and each virus pellet was 
resuspended in 50 µl HBSS. The virus suspensions were stored in sterile screw-cap 
reaction tubes at 4 °C until second harvest. 
 Transfection mixture 
 SIN Lentivirus SIN Retrovirus Retrovirus 
viral plasmid SIN-LVs SIN-RVs pCLMFGGFP 
packaging 
plasmids 
pMDLg/pRRE pCMV-gagpol pCMV-gagpol 
RSV-Rev pMD.G pMD.G 
pMD.G   
 CaCl2 CaCl2 CaCl2 
reagent 2x BBS 2x BBS 2x BBS 
Materials and Methods 
29 
 
24 hours after first harvest, the supernatants in cell dishes were collected and centrifuged 
as mentioned above. The virus suspensions from first and second harvest were mixed and 
transferred into a centrifuge tube on top of a 2 ml 20% (w/v) sucrose cushion. The viruses 
were concentrated by an ultracentrifuge with a SW55Ti rotor at 53,500g at 17 °C for 2 
hours. After discarding the medium, the virus pellet was resuspended in 120 µl HBSS and 
the virus suspension was transferred to sterile screw-cap reaction tubes. The tubes were 
shacked at 1,400 rpm at 16°C for 45 minutes and centrifuged at 16,000g for 60 seconds to 
spin down debris. The opaque supernatants were aliquoted in sterile screw-caps reaction 
tubes and stored at -80 °C. 
 
2.1.5. Measurement of virus titer  
Biological titer 
If LVs/RVs carry a fluorescence reporter gene, the biological virus titers were measured by 
infecting cells with serial dilutions of the virus-preparation combined with flow cyctometry 
analysis. Therefore, 1x10
5
 NIH 3T3 (murine embryonic fibroblasts) cells per well were 
seeded on 24-well cell culture plate. On the next day, 1 μl virus was dissolved in 330μl 
DMEM and mixed completely (Dilution No.1). Then, 30μl of Dilution No. 1 was further 
transferred in new reaction tube with 300μl DMEM and mixed completely (Dilution No. 2). 
The Dilution No. 3 and No. 4 were prepared according to the same procedure as for No. 2. 
Finally, all serial dilution of No. 1 to 4 including control (medium without virus) were 
applied to 5 individual wells of 24-well plate growing NIH 3T3 cells. Another well was 
used for cell counting. Medium was changed 18 hours later and cells were always 
incubated at 37 °C. After 72 hours, NIH 3T3 cells were washed with PBS, trypsinized and 
fixed with 4% paraformaldehyde (PFA) for 15 minutes on ice. Subsequently, cells were 
spun down by centrifugation with 1100 rpm at 4ºC and resuspended in 1 ml PBS for flow 
cyctometry analysis (Pfeifer & Hofmann, 2009). The multiplicity of infection (MOI) and 
the biological titer of the virus in infectious units (IU) per ml (IU/ml) were calculated as 
follows  
 
MOI = -ln (percentage of eGFP-negative cells/100) 
Virus titer (IU/ml) = (No. of infected cells) x (MOI) x (dilution factor) x 1000 
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4% PFA  
paraformaldehyde 4 g 
1X PBS Ad 100 ml 
pH 7.4 
stored at -20°C 
 
Physical titer 
To determine the physical titer of lentiviral vector preparations Enzyme Linked 
Immunosorbent Assays (ELISA) against reverse transcriptase or the lentiviral p24 capsid 
protein were used. In the present study, a commercially available reverse transcriptase 
ELISA was applied (see Reagents) giving the ng reverse transcriptase/µl virus suspension. 
Besides, the physical titer can be referred to as the integrant numbers of provirus per 
genome in transduced host cells (titer in integrants/ml) by applying quantitative real time 
PCR (2.6.3).  
 
2.2. Cultivation of pluripotent stem cells  
2.2.1. Cultivation of ES and iPS cells 
ES cells including R1 (3.1) and D3 (3.2) ES cell line and iPS cells including iPS and iPS-
Oct-GFP cell lines (3.2.2) were stored in liquid nitrogen. One day before thawing cells, cell 
culture dishes or plates were coated with a layer of mitotically inactived murine fibroblast 
cells. They were used a feeder cells that preserve the self-renewal and maintain the 
pluripotency of pluripotent stem cells (Pfeifer & Hofmann, 2009; Wobus & Boheler, 2005). 
Cells were briefly thawed in a 37°C water bath and transferred to 15-ml conical tube with 5 
ml medium. After centrifugation at 200 g for 5 minutes, the supernatants were aspirated 
and cells were resuspended in fresh medium. Then, ES or iPS cells were cultured at 37 °C, 
5% CO2. In order to maintain the pluripotency of cells, cell medium was changed every 
day. Moreover, cells were split on new dishes before cell grew to high confluency or they 
were split if cell colonies became visibly large or if they get in contact to each other. 
iPS cell lines used in present work were kindly provided by Jun.-Prof. Dr. Philipp Sasse. 
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2.2.2. Transduction with LVs/RVs 
In order to transduce pluripotent cells efficiently, viral transduction was performed after 
single cells have attached to the feeder cells layer. Viral transduction of ES or iPS cells 
was performed by removing the medium and incubating the cells with fresh medium 
containing dissolved virus overnight. The required amount of virus was calculated as 
follows 
  
amount of virus (µl) = cell numbers per well × MOI / physical titer (Integrants/ml) 
 
Since LVs can also transduce feeder cells highly efficient, the number of feeder cells had 
to be considered for the calculations.  
The medium containing virus was replaced with fresh medium 18 hours after transduction. 
The viral transduced cells were either further cultured until next regular passaging of cells 
or frozen in cell freezing medium (ES or iPS cell medium supplemented with 10% DMSO) 
at -80 °C. 2 days later the frozen cells were stored in liquid nitrogen. 
 
R1 ES cell medium (3.1) 
DMEM (Cat. No. 31966) 
20% FCS 
0.1mM ß-mercaptoethanol 
100 U/ml Penicillin G  
100 μg/ml Streptomycin. 
1,000 U/ml LIF 
 
D3 ES cell Medium (3.2) 
DMEM (Cat. No. 41966) 
15% FCS 
1x non-essential amino acids (MEM) 
0.1mM ß-mercaptoethanol 
100 U/ml Penicillin G 
100 μg/ml Streptomycin. 
1,000 U/ml
 
LIF
 
iPS cell medium 
DMEM (Cat. No. 41966) 
15% FCS 
1x non-essential amino acid (MEM) 
0.1mM ß-mercaptoethanol 
100 U/ml Penicillin G 
100 μg/ml Streptomycin 
 
1,000 U/ml LIF 
3 µM CHIR 99021 
4 µM PD 0325901 
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2.2.3. Generation of ES cell clones 
After transduction of ES cells with LVs/RVs, 100 to 500 ES cells were seeded on 100-mm 
tissue dishes coated with feeder cells (4x10
6
 feeder cells per dish). 7 days later the feeder 
cells around single colonies were removed by circling with a filtered pipette tip connected 
to pipette P20 (Gibson). The ES cell colonies were scraped slightly to dislodge the colonies 
from the feeder cell layer. Subsequently, ES cell colonies were sucked into the pipette tips 
and transferred into a well of a 24-well plate containing 120 µl 0.05% trypsin/EDTA. After 
incubation at 37°C for 5 minutes, the ES cell colonies were resuspended gently to dispense 
to single cells. Three times 40 µl of the cell suspension was each transferred into a 
separated freshly prepared well of a 24-well plate with adherent feeder cells (1x10
5
 feeder 
cells per well) and 300 µl of ES cell medium, respectively. Then, ES cells were further 
cultivated for 3-4 days until 70% confluency. The three wells per ES cell clone were either 
used for Southern blot analysis, flow cyctometry analysis or for freezing of cells. 
The SIN-LV- and SIN-RV-transduced ES cell clones for epigenetic regulation analysis 
were kindly provided by Dr. Andreas Hofmann. 
 
2.2.4. Differentiation of ES cells 
Differentiation of ES cells in vitro was performed by culturing ES cells as embryoid bodies 
(EBs) in the absence of mouse embryonic fibroblast feeders and leukemia inhibitory factor 
(LIF) (Wobus & Boheler, 2005) in liquid mass culture (Boheler et al, 2002; Doetschman et 
al, 1985). ES cells were trypsinized and then transferred in differentiation medium. The 
cell suspensions were incubated in sterile petri dishes at 37°C with 80 rpm shaking for 14 
days. The differentiation medium was replaced every 3 days. At the end of the procedure 
the EB aggregates were formed. 
 
Differentiation medium 
IMDM (Cat. No. 12240) 
20% (v/v) FCS 
0.1 mM ß-mercaptoethanol 
100 U/ml Penicillin G / 100 μg/ml Streptomycin 
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2.3. Extraction of genomic DNA 
Genomic DNA (gDNA) of ES cells was extracted by the classical phenol-chloroform 
method: After washing of cells in a 6-well or 24-well plate with PBS, PBS was removed 
and cells were treated with 500 µl extraction buffer per well for 5 minutes at 37ºC. The 
dissolved cells were resuspended by gently pipeting. Subsequently, the samples were 
transferred into 1.5ml reaction tubes and incubated in a thermomixer at 800 rpm shaking at 
55ºC overnight. On the next day, 500µl Phenol/chloroform/isoamyl alcohol (50:48:2) was 
each added to the samples and the tubes were inversed vigorously. After centrifugation at 
13000 rpm for 15 minutes, the upper aqueous phase containing gDNA was each transferred 
into a new tube without residual of cells. For a second removal of the residues, 500 µl 
chloroform was added to the gDNA solution and mixed well. After centrifugation with 
13000 rpm for 15 minutes, the upper aqueous phase containing gDNA was transferred into 
a new reaction tube. For gDNA precipitation, 800 µl isopropanol was added to the aqueous 
phase and gDNA was spun down by centrifuging at 13000 rpm for 15 minutes. The gDNA 
pellets were dried at 37ºC for 30 minutes and finally dissolved in 100 µl H2O at 55ºC 
overnight. gDNAs were stored at 4ºC. 
 
DNA extraction buffer 
5 mM EDTA 
0.2% (w/v) SDS 
200 mM NaCl 
0.1 mg/ml Proteinase K 
 
For isolation of gDNA from mouse tail, 0.3 to 0.5 cm of the mouse tail was minced and 
treated with 500 µl extraction buffer at 55 °C overnight. The further procedure was 
performed as mentioned above.  
 
2.4. Isolation of total RNA and cDNA synthesis 
Total RNA of cells was extracted by Guanidin-isothiocyanate/phenol (Chomczynski & 
Sacchi, 1987) using peqGOLD Tris-FAST (peqLAB). Firstly, cells from a well of a 6-well 
plate were washed with PBS. After removing the PBS, 1ml of peqGOLD Tris-Fast
®
 was 
each added to cells. After incubation for 5 minutes at RT, dissolved cells were resuspended 
by gently pipeting. The following steps were progressed according to the manufacturer’s 
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instructions. The measurement of total RNA’s concentration was performed by using a 
photometer (Eppendorf). 
For cDNA synthesis by reverse transcription of RNA, Transcriptor First Strand cDNA 
Synthesis Kit (Roche) and random hexamer primers were applied according to the 
manufacturer’s instructions.  
 
2.5. Isolation of protein  
Cells of wells from a 6-well or 24-well plate were washed with PBS. After removing of 
PBS, cells were treated with 200 µl Radioimmunoprecipitation assay (RIPA) lysis buffer 
containing complete protease inhibitor (Roche) for 5 minutes at RT and then resuspended 
by gently pipeting. Thereafter, protein lysates were centrifuged at 13000 rpm at 4ºC for 15 
minutes. The upper protein lysate solutions were each transferred in a new tube and stored 
at -80ºC. Protein concentration was measured by using Coomassie blue Bradford method 
(Bradford, 1976). The Bradford method is based on the binding of amino acids to 
Coomassie blue G250 dye resulting in an absorbance shift. 2 μl of protein lysate was each 
added to 98 μl 0.15 M NaCl solution. After addition of 1 ml Coomassie solution, samples 
were incubated for exactly 2 minutes at RT and the absorbance was measured by a 
photometer at 595 nm (Eppendorf). A calibration curve for absorbance was performed by 
using BSA standards of known protein concentration. 
 
 
RIPA lysis buffer 
150 mM NaCl 
50 mM Tris (pH 7.5) 
0.1% (w/v) SDS 
0.25% (w/v) Deoxycholic acid sodium 
salt 
1% Nonidet P40 
stored at 4ºC 
 
Coomassie blue Bradford regant 
Coomassie G250 100 mg 
98%(v/v) EtOH 50 ml 
85% (v/v) H3PO4 100 ml 
H2O Ad 1 l 
  
stored in darkness at 4°C  
 
For isolation of protein from mouse tails, 0.3 to 0.5 cm of the mouse tail was minced and 
homogenized by using a hand mixer in a reaction tube with 500 µl RIPA buffer at 4 °C. 
The further procedure was performed as mentioned above.  
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2.6. Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) (Saiki et al, 1988) is a widely used method for 
amplification of defined nucleic acid sequences. Within the first step (denaturation) 
double-stranded DNA is melted by heat denaturation. The second step (annealing) allows 
annealing of forward and reverse primers to the complementary sequence, respectively. In 
the third step (extension) the DNA polymerase synthesizes a new complementary DNA 
strand by adding deoxynucleoside triphosphates (dNTPs) in 5' to 3' direction. The repeated 
cycles of these three steps results in production of huge amounts of DNA. 
 
2.6.1. Genotyping PCR of transgenic mice 
The following GFP primers were used to detect the eGFP gene from integrated provirus in 
probably transgenic mice resulting from subzonal injections with SIN-LV/RV. AP18 
(forward) and KISAX (reverse) primers were used as PCR loading controls targeting 
housekeeping gene Protein Kinase G 1 (PKG1). The TaqCORE kit (Qbiogen) was applied 
for genotyping PCR reactions by using the following PCR preparation and programs. 
 
Primer name Sequence of genotyping PCR primers  
GFP forward 5’-ATGGCTTCGTACCCCTGCCA-3’ 
GFP reverse 5’-TCAGTTAGCCTCCCCCA-3’ 
AP18 5’-GCTCTACTCGTCCGAAACCT-3’ 
KISAX 5’-GCCGCTCGAGTAAGGGAAACTAATGAGAAACTGCT-3’ 
  
PCR preparation 
gDNA  3 µl 
GFP forward (10 pmol/μl) 2.5 µl 
GFP reverse (10 pmol/μl) 2.5 µl 
dNTPs (1.25 mM/each) 8 µl 
10 x reaction buffer 5 µl 
DNA polymerase Taq 0.5 µl 
H2O 28 µl 
 
Total  
 
50 µl 
 
PCR program 
Step Temperature  Time (seconds) 
1. 95 °C 300 
2. 95 °C 30 
3. 57°C  30 
4. 72 °C 30 
5. 72 °C 300 
   
Step 2 to 4 was repeated for 40 cycles 
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PCR preparation 
gDNA  3 µl 
Ap18 (10 pmol/μl) 2.5 µl 
KISAX (10 pmol/μl) 2.5 µl 
dNTPs (1.25 mM/each) 8 µl 
10 x reaction buffer 5 µl 
DNA polymerase Taq 0.5 µl 
H2O 28 µl 
 
Total  
 
50 µl 
 
PCR program 
Step Temperature  Time (seconds) 
1. 95 °C 300 
2. 95 °C 30 
3. 58°C  30 
4. 72 °C 30 
5. 72 °C 180 
   
 
Step 2 to 4 was repeated for 30 cycles  
 
2.6.2. Cloning PCRs for generation of LVs expressing TK 
For the generation of TK expressing LV constructs, different promoters of pluripotency 
genes as well as the cDNA of Herpes simplex TK were cloned after PCR amplification 
using mi-Pfu DNA polymerase (Metabion). The mi-Pfu DNA Polymerase catalyzes DNA 
polymerization and possesses also a proofreading activity to excise base misinsertions 
rapidly that may occur during the polymerization process. 
The promoters of pluripotency genes Nanog and Oct-3/4 including enhancer elements 
(Boer et al, 2007) were amplified from gDNA of wildtype mice using “cloning” PCR. The 
promoters of pluripotency genes EOS-C3 and EOS-S4 were amplified from plasmids: PL-
SIN-EOS-C(3+)-EiP and PL-SIN-EOS-S(4+)-EiP (Hotta et al, 2009). The four promoters 
were each cloned into either the SalI and BamHI or ClaI and BamHI site of the 3rd 
generation LV plasmid pRRLSIN.cPPT.eGFP.WPRE (Follenzi et al, 2000; Pfeifer & 
Verma, 2001b).  
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Primer name sequence of Cloning PCR primers  
Nanog forward 5’-cgtgatGTCGACAATTTCTTCTTCCATTGCTTAGACGG-3’ 
                  SalI 
Nanog reverse 5’-tgcgccGGATCCAAGGGATTTCTGAAAAGGTTTTAGGC-3’ 
                  BamHI 
Oct-3/4 forward 5’-ttcattATCGATTCTAGGCACGCTTAGGGC-3’ 
                ClaI 
Oct-3/4 reverse 5’-ttcattAGATCTCCGAGCCGGGGGCCTGGTGG-3’ 
                BglI 
EOS-C3 forward 5’-ggaaATCGATTTTATCCAGCCCTCACTCCT-3’ 
                ClaI  
EOS-C3 reverse 5’-aattGGATCCTGGCTTTACCAACAGTACCG-3’ 
             BamHI 
EOS-S4 forward 5’-ggaaATCGATTTTATCCAGCCCTCACTCCT-3’ 
               ClaI 
EOS-S4 reverse 5’-aattGGATCCTGGCTTTACCAACAGTACCG-3’ 
                  BamHI 
 
After cloning of the promoter the eGFP transgene was each replaced with TK cDNA of 
herpes simplex virus between the restriction sites BamHI and XhoI. TK cDNA was 
amplified from a plasmid containing TK cDNA that was originally obtained from Promega. 
For the generation of the double cassette LV construct EOS-S4-TK-PGK-Hygromycin 
(STPH) (see also Figure 49), an expression cassette with hygromycin resistance gene under 
the control of the PGK promoter was cloned into the LV construct EOS-S4-TK (ST) 
between TK cDNA and the WPRE element. The cDNA of the hygromycin resistance gene 
was amplified from a plasmid that was kindly supplied by Prof. Fleischmann’s lab. The 
following PCR preparations and programs were used for cloning PCR reactions. The 
annealing temperature varied depending on the primer pair used. 
 
Transgene Sequence Cloning PCR primers  
TK forward 5’-gattGGATCCATGGCTTCGTACCCCTGCCA-3’ 
             BamHI 
TK reverse 5’-aattCGCGAGTCAGTTAGCCTCCCCCA-3’ 
              XhoI 
hygromycin 
forward 
5’-ttggGGATCCAGCCGCCACCATGAAAAAGC-3’ 
            BamHI 
hygromycin 
reverse 
5’-ggttCTCGAGATCGATCTATTCCTTTGCCCTCGGACGAGTGC-3’ 
               XhoI-ClaI 
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PCR preparation 
gDNA/plasmid DNA 5 µl 
primer forward (10 pmol/μl) 2.5 µl 
primer reverse (10 pmol/μl) 2.5 µl 
dNTPs (2.5 mM/each) 4 µl 
10 x reaction buffer 5 µl 
mi-Pfu polymerase (2.5 units) 0.5 µl 
H2O 30.5 µl 
 
Total  
 
50 µl 
PCR program 
Step Temperature  Time (seconds) 
1. 95 °C 300 
2. 95 °C 30 
3. 55-60°C  30 
4. 72 °C 300 
5. 72 °C 600 
   
Step 2 to 4 repeated for 40 cycles  
 
2.6.3. Quantitative real-time PCR for analysis of provirus integration numbers 
For an accurate detection of the provirus integration number using quantitative real-time 
PCR (qPCR), the supercoiled gDNAs were firstly digested using restriction enzymes to 
obtain smaller DNA fragments that are more suitable for subsequent qPCR reactions. The 
gDNAs were obtained as described in section 2.3. Around 5 µg gDNA was digested with 5 
units of each enzyme BamHI and EcoRI at 37 °C overnight. The digested DNA was 
precipitated with 500 µl 100% isopropanol by inverting and subsequent freezing at -80 °C 
for at least 1 hour. Afterwards, digested DNA was spun down at 13,000 rpm at 4 °C for 15 
minutes. After discarding supernatants, 500 µl 70% ethanol was added and tubes were 
inverted several times. Subsequently, DNA was spun down again at 13,000 rpm at 4 °C for 
15 minutes. After discarding supernatants, the digested DNAs were dried at 37 °C for 1 
hour. Finally, the digested DNAs were dissolved in 30 µl H2O at 55 °C overnight and 
stored at 4 °C. 
The qPCR analysis was performed using iQ5 Real-time PCR System and the iQ Multiplex 
Powermix (BioRad) in 25 µl final volumes according to the manufacturer’s instructions. 
To measure exactly the LV integrants per genome of transduced cells or in transgenic mice, 
a duplex qPCR approach was used in which the copies of the LVs and the DNA loading 
(housekeeping gene, i.e. Burkitt lymphoma receptor 1 (BLR1) gene) are measured in one-
and-the-same tube. Integrated provirus DNA was detected by using a FAM-labeled Late-
RT probe and Late-RT primers and the house keeping gene BLR1 was detected by using 
Texas-Red–labeled BLR1 probe and BLR1 primers (Pfeifer et al, 2010). The following 
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PCR preparations and program were used for qPCR reactions. For each sample the reaction 
was performed (at least) in triplet. 
 
Primers/Probes Sequence qPCR primers/probes  
Late-RT forward 5’-TGTGTGCCCGTCTGTTGTGT-3’ 
Late-RT reverse 5’- GAGTCCTGCGTCGAGAGAGC-3’ 
Late-RT probe 5’-FAM- CAGTGGCGCCCGAACAGGGA-BHQ1-3’ 
BLR1 forward  5 -´CGGAGCTCAACCGAGACCT-3  ´ 
BLR1 reverse 5 -´TGCAAAAGGCAGGATGAAGA-3 
BLR1 probe 5 -´TexasRed-CTGTTCCACCTCGCA GTAGCCGAC-BHQ1-3  ´
 
PCR preparation 
digested gDNA  2 µl 
Late-RT for (5 pmol/μl) 1.5 µl 
Late-RT rev(5 pmol/μl) 1.5 µl 
Late-RT probe (5 pmol/μl) 1 µl 
BLR1 for (5 pmol/μl) 1.5 µl 
BLR1 rev (5 pmol/μl) 1.5 µl 
BLR1 probe (5 pmol/μl) 1 µl 
iQ Powermix 12.5 µl 
H2O 2 µl 
PCR program 
Step Temperature  Time (seconds) 
1. 95 °C 180 
2. 95 °C 15 
3. 60°C  60 
   
Step 2 to 3 was repeated for 40 cycles  
 
 
Total 25 µl 
 
The absolute copy number per genome can be determined by comparison of the cycle 
threshold values from virus specific probe versus the BLR1 probe. Copy numbers were 
evaluated as follows  
 
Copy numbers = 2
ΔCt
 with  ΔCt=Ct(BLR1)-Ct(Late-RT) (Pfeifer et al, 2010). 
 
2.6.4 Quantitative real-time PCR for TK expression on mRNA level 
Quantification of TK expression on mRNA level was performed by using the iQ SYBR 
Green Supermix (Bio-Rad) on iQ5 Real-time PCR System (Rio-Rad) with the following 
specific primer combinations. As loading control GAPDH was used. Preparation of cDNA 
is explained in detail in 2.4. 
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primers Sequence qPCR primers  
TK-RT forward 5’-GATGACTTACTGGGCAGGTG-3 
TK-RT reverse 5’-GATGGCGGTCGAAGATGAG-3’ 
GAPDH-RT forward 5’-CCACTCACGGCAAATTCAAC-3’ 
GAPDH-RT reverse 5-‘GTTCACACCCATCACAAACATG-3’ 
 
PCR preparation 
cDNA (2ng/µl) 2 µl 
RT forward (5 pmol/μl) 1.5 µl 
RT reverse (5 pmol/μl) 1.5 µl 
iQ SYBR Green Supermix 12.5 µl 
H2O 7.5 µl 
 
Total  
 
25 µl 
 
PCR program 
Step Temperature  Time (seconds) 
1. 95 °C 180 
2. 95 °C 30 
3. 57°C  30 
4. 72 °C 30 
   
Step 2 to 4 were repeated for 40 cycles 
 
Melting curve 
Step Temperature  Time (seconds) 
5. 72 °C 180 
6. 55 to 95°C 30 
Step 6 was repeated for 81 cycles. 0.5°C 
 was increased and acquisition per cycle. 
 
Relative quantification of mRNA levels was performed based on the cycle threshold (Ct) 
values of the amplification curves as follows 
 
 relative mRNA level = 2
ΔCt
 with ΔCt = Ct(GAPDH)-Ct(TK) 
 
2.7. Separation, isolation and cloning of DNA 
2.7.1. Enzyme restrictions of DNA 
For digestion of double stranded DNA on specific sequences, restriction enzymes are the 
most important tool. Restriction enzymes were purchased from NEB. The digestion of 
DNA was performed according to the manufacturer’s instructions using the buffers supplied 
with the enzymes by NEB. The general reaction condition was used as follows 
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DNA digestion 
DNA  5 µg 
Restriction enzyme 20 units 
10 x buffer 3µl 
10 x BSA 3µl 
H2O Ad 30 µl 
Reaction was incubated at 37 °C over night. 
 
2.7.2. Separation and elution of digested DNA  
Nucleic acids are negatively charged and DNA fragments of different molecular weights 
can be separated by gel electrophoresis. By staining the gels with the fluorescent dye 
ethidium bromide visualization of the separated DNA under UV light (302nm) can be 
obtained. A DNA marker (1kb Ladder, Invitrogen) is used to determine the size of DNA-
fragments.. Agarose gel electrophoresis is a common method of separating and analyzing 
DNAs within the size of 0.5 to 12 kb. Therefore, agarose was melted in 1x TBE by using a 
microwave and ethidium bromide (800 ng/ml final) was added before pouring in a gel tank. 
The gel electrophoresis was performed in 1x TBE as running buffer and a voltage of 100V 
was applied.  
 
10x TBE buffer 
Tris  540 g 
boric acid 275 g 
0.5M EDTA pH 8.0 200 ml 
H2O Ad 5 l 
 
For elution of DNA from agarose gels the target DNA fragment was cut out and eluted by 
using the GFX
TM
 System (Amersham) according to the manufactory’s instruction. 
2.7.3. Ligation of DNA  
For reconstructing new virus plasmids, T4 DNA ligase (NEB) was used for catalyzing the 
formation of a phosphodiester bond between juxtaposed 5' phosphate and 3' hydroxyl 
termini in duplex DNA. The following ligation reaction was used in general. 
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DNA ligation 
DNA (vector) 50 ng 
DNA (insert) 200 ng 
T4 DNA ligase 2.5 units 
10 x Ligation buffer 1,5µl 
H2O Ad 15 µl 
The reaction mixture was incubated at 16°C over night. 
 
On the next day, 7 µl of the DNA ligation was each transformed into chemical competent 
E. coli. XL1 blue cells. The transformation was performed as already described for the 
retransformation of plasmids (2.1.3).  
 
2.8. Southern Blot 
Southern Blot analysis (Southern, 1975) is a recommended method to identify specific 
genes in gDNA and the procedure is described in detail below. Briefly, gDNA was 
digested with a suitable restriction enzyme to obtain smaller fragments for the analysis. 
DNA fragments were then separated by agarose gel electrophoresis (2.7.2) and transferred 
from the agarose gel to a nylon membrane by blotting. Finally, the membrane with DNA 
was hybridized with a radioactive probe that has a specific complementary sequence of the 
target DNA. The radioactive labeled target DNA was detected by use of a PhosphorImager 
(Southern, 1975) or by exposing to an autoradiography film that can be developed by 
AGFA CP 1000 film processor. 
 
2.8.1 gDNA digestion for Southern blot analysis 
For analysis of integration numbers of provirus DNA in host cells or transgenic mice, 
gDNA was isolated (2.3) and digested with the restriction enzyme BamHI (NEB) at 37ºC 
over night. Integrated provirus DNA in the host genome can only be digested once with 
BamHI. The size of digested DNA fragments depends on the integration site and thus, on 
further restriction sites in the genome (Figure 10). For the analysis of the methylation 
status of integrated provirus, an additional methylation-sensitive enzyme was used to 
digest gDNA (3.1.4). 
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Figure 10: Schematic illustration of integrated provirus. The gDNA of SIN-LV-transduced cells was 
digested with BamHI for Southern blot analysis.   
 
2.8.2. DNA denaturation 
The digested DNA was loaded on a 0.7% (w/v) agarose gel and separated by 
electrophoresis. The agarose gel was then visualized under the UV light transilluminator, 
GelDoc® XR (Geldoc) together with a phosphorescent ruler and an image was taken. 
Thereafter, DNA in the agarose gel was depurinated by bathing in 0.2M NaCl for 10 
minutes and neutralized by bathing in 0.5M NaOH/1.5M NaCl for 30 minutes. This step 
enables a denaturation of the DNA leading to single stranded DNA that can be hybridized 
with a probe. Denaturation was performed in 0.5M Tris/3.0M NaCl (pH 7.4) for 30 
minutes. 
 
2.8.3. Blotting 
For transferring the single stranded DNA from the agarose gel onto a nylon membrane, the 
transfer agent 10x SSC buffer was used for blotting. The blot was set up as sandwich (from 
bottom to top): large plastic dish with 10x SSC buffer, sponge, Whatman filter paper, gel, 
nylon transfer membrane (Gene Screen Plus Transfer Membrane; Perkin Elemer Life 
Science), Whatman filter paper and blotting paper towel. During the transferring of buffer 
from dish to blotting paper by capillary action overnight, DNA was transferred onto the 
membrane. For fixation of DNA on the membrane a CL-1000 UV cross-linker (UVP) was 
used at 120,000 µJ/cm
2
 for 1 minute. 
 
20x SSC 
NaCl 350 g 
Na3-citrate-2H2O 176 g 
H2O Ad 2 l 
pH (with HCl) 7.0 
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2.8.4. Probe hybridization 
An eGFP-probe was used for hybridization with provirus DNA containing eGFP cDNA. 
For preparing the eGFP-probes, eGFP cDNA (748 bp) was digested from a LV plasmid 
with restriction enzymes BamHI and SalI. 200ng probe-cDNA in 14 µl H2O was boiled at 
97ºC for 10 minutes and then cooled down on ice for 10 minutes. Afterwards, eGFP cDNA 
was labeled with deoxynucleoside triphosphates (dATP, dGTP and dTTP) and phosphorus-
32 labeled dCTP (α-P32-dCTP) (PerkinElmer) by using the Random Primed Labeling Kit 
(Roche). After incubation at 37ºC for 30 minutes, radioactive labeled-eGFP probe was 
purified through NICK Columns (Amersham) according to the manufactory’s instructions. 
The radioactivity of the probe was measured using a radioactivity counter. A proper 
amount of radioactive labeled-probe was transferred into 1ml TE buffer in a 15 ml tube 
and heated in water bath at 100°C for 10 minutes. 
The membrane with fixed DNA was transferred into a glass column and hybridized with 
Church buffer including probe by rotating at 60 ºC over night. On the next day, the 
membrane was washed twice with 2x SSC/1% (w/v) SDS at 60 ºC for 20 minutes and 0.4x 
SSC/1 % (w/v) SDS for 40 minutes. The autoradiography film was put on the membrane 
and exposed for 7 days. Finally, the film was developed by AGFA CP 1000 film processor. 
 
eGFP probe 
eGFP cDNA 14 µl 
mix of dATP, dGTP, dTTP 6 µl 
Hexanucleotide 4 µl 
αP32-dCTP 14 µl 
Klenow enzyme 2 µl 
 
1x TE buffer 
1M Tris (pH 8.0) 5 ml 
0.5M EDTA (pH 8.0) 1ml 
H2O Ad 500 ml 
  
  
 
Church buffer 
20% (w/v) SDS 175 ml 
ssDNA 5 ml 
BSA 5 g 
1M Na2HPO4 193.5 ml 
1M NaH2PO4 56.5 ml 
0.5M EDTA pH 8.0 1 ml 
H2O Ad 500 ml 
 
ssDNA 
salmon sperm DNA 500 mg 
H2O Ad 50 ml 
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2.9. Western Blot 
Western blot is a widely used tool for detection of specific proteins by using specific 
antibodies. Briefly, proteins were separated using sodium dodecyl sulfate-polyacrylamide-
polyacrylamid Gelelectrophorese (SDS-PAGE) (Burnette, 1981). Afterwards, proteins 
were electro-transferred onto polyvinylidene difluoride (PVDF) membranes. The 
transferred proteins on the membrane were then specifically targeted using specific 
antibodies and visualized was performed by a chemiluminescent detection method. 
For protein separation, acrylamide gels were used, i.e. a stacking gel on top of a separating 
gel. The polymerization of gel was each initiated by adding ammonium peroxodisulfate 
(APS) as radical initiator and TEMED as catalysator. The percentage of acrylamide leads 
to a varying property of gels for stacking and separating of proteins of different molecular 
weights. 
Protein lysates (2.5) were diluted to optimal concentrations of 2-5 µg/µl with RIPA buffer 
containing 6x Laemmli loading buffer (Laemmli, 1970) supplemented with 5% (v/v) ß-
mercaptoethanol. The proteins were boiled on a thermomixer at 97 °C for 5 minutes and 
separated by using SDS-PAGE with 12% separating and 5% stacking gel. Subsequently, 
proteins were transferred to PVDF membranes at 220mA for 1 hour using a semi-dry 
method. 
After transferring, the membrane was rinsed once in methanol and subsequently in water. 
The membrane was blocked in 5% (w/v) skim milk in Tris-buffered saline with 0.1% 
Tween-20 (TBS-T) for 30 minutes. After washing three times with TBS-T buffer, the 
membrane was incubated with the primary antibody against either GFP, β-actin or tubulin 
at RT for 1 hour. In addition, the membrane was incubated at 4 °C over night when using 
the primary antibody against TK. After washing three times with TBS-T buffer, the 
membrane was incubated with the suitable secondary antibody conjugated to Horse Radish 
Peroxidase (HRP) (Jackson ImmunoResearch) at 1:10,000 dilution. For detection of the 
HRP signal, the SuperSignal west pico chemiluminescent substrate (Thermo), ECL 
detection film (GE Healthcare) and film developer (AGFA) were used. The following 
antibodies were used. 
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Name of the antigen Company  Dilution 
GFP  Clontech 1:1000 
β-actin Abcam 1:1000 
TK Santa Cruz Biotechnology 1:500 
tubulin Dianova 1:1000 
mouse-HRP Jackson ImmunoResearch 1:10000 
goat-HRP 
 
Jackson ImmunoResearch 1:10000 
12% Separating gel (20 ml) 
H2O 6.9 ml 
30% Acrylamide (Roti- 
phorese
®  
Gel 30) 
8 ml 
4x 1.5M Tris-Cl/0.4% SDS 
pH 8.8 
5 ml 
20% (w/v) APS 100 µl 
TEMED 8 µl 
 
5% Stacking gel (6 ml) 
H2O 3.5 ml  
30% Acrylamide (Roti- 
phorese
®  
Gel 30) 
1 ml 
4x 0.5M Tris-Cl/0.4% 
SDS pH 6.8 
1.5 ml 
20% (w/v) APS 30 µl 
TEMED 6 µl 
  
4x 1.5M Tris-Cl/0.4% SDS pH 8.8 
Tris 91 g 
SDS 2 g 
H2O Ad 500 ml 
pH (with HCl) 8.8   
  
4x 0.5M Tris-Cl/0.4% SDS pH 6.8 
Tris 9.06 g 
SDS 0.6 g 
H2O Ad 150 ml 
pH (with HCl) 6.8   
 
 
6x Laemmli buffer 
4x 0.5M Tris-Cl/ 0.4% SDS 
pH 6.8 
6 ml 
Bromphenol blue 0.12 g 
Glycerol 9 ml 
SDS 2.4 g 
H2O Ad 20 ml 
10x Electrophoresis buffer  
Tris 60.2 g 
Glycine 288 g 
H2O Ad 2 l 
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Transfer buffer 
10x Electrophoresis buffer 100 ml 
Methanol 200 ml 
H2O Ad 1 l 
  
 
 
 
10x TBS 
Tris 24.2 g  
NaCl 160.46 g 
H2O Ad 2 l 
pH (with HCl) 8.0 
 
 
TBS-T buffer 
10x TBS 100 ml 
Tween-20 1 ml 
H2O Ad 1 l 
pH (with HCl) 8.0 
 
2.10. Bisulfite Sequencing 
The bisulfite sequencing is a method to determine the 5-methyl-cytosine resulting from 
methylation of cytosine in CpG nucleotides (Clark et al, 1994). By treating DNA with 
sodium bisulfate, all cytosine residues are converted to uracil except cytosines carrying 5-
methyl residues (Frommer et al, 1992). The target fragments are amplified with strand-
specific primers (Frommer et al, 1992) and then cloned into plasmids for further 
sequencing. The numbers and positions of methylated CpG sites can be determined by 
comparing to unmethylated ones. 
 
2.10.1. DNA digestion and purification 
5 µg gDNA (2.3) was digested with restriction enzyme EcoRI. DNAs were then extracted 
with phenol and precipitated with 500µl 96% (v/v) ethanol as described before (2.6.3). 
DNA pellets were dried by vacuum in a speed vac and further dissolved in TE buffer (10 
mM Tris, 0.1 mM EDTA, pH 8.0). The DNA was fully denatured by twice shock freezing 
at -80ºC and thawing at RT. DNA was then boiled at 100 ºC for 10 minutes and 
concentrations were detected using a photometer (Eppendorf). 
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2.10.2. Bisulfite-conversion of DNA 
2μg digested and purified DNA was added to NaOH solution (0.3 M NaOH final) in total 
volume of 20μl and denatured at 37 ºC for 15 minutes. Subsequently, 120 μl BS solution 
was added and DNA was incubated in a themocycler (Biometra) using the following steps: 
15 cycles with 30 seconds at 95 °C and 15 minutes at 50 °C. Finally, the DNA was purified 
with Wizard DNA Clean-Up System (Promega) according to the manufactory’s 
instructions. DNA was then eluted with 103.6 μl TE buffer. 6.4 μl NaOH (5M) was added 
to the eluted DNA solution and the solution was incubated at 37 °C for 15 minutes. After 
adding of 47 μl NH4OAc (10M, pH 7.0) for neutralization, DNA was precipitated with 500 
μl 96% (v/v) ethanol , dried in vacuum and dissolved in 50 μl TE buffer. DNA was stored 
at -20°C.  
 
BS solution 
3.6 M Sodium bisulfite  
0.6 mM Hydroquinone 
pH 5.0 
 
 
 
 
10 μl converted DNA was then used for amplification of eGFP resulting from provirus 
integration. The following primers, PCR preparation and program were used. 
 
Primer name Sequence of primers  
GFP-BS forward 5’- GGGTATAAGTTGGAGTATAA-3’ 
GFP-BS reverse 5’-CTCCAACAAAACCATATAAT-3’ 
 
PCR preparation 
BS convert DNA  10 µl 
GFP-BS forward (10 pmol/μl) 2.5 µl 
GFP-BS reverse (10 pmol/μl) 2.5 µl 
dNTPs (1.25 mM/each) 8 µl 
10 x reaction buffer 5 µl 
DNA polymerase Taq 0.5 µl 
H2O 21 µl 
 
Total  
 
50 µl 
PCR program 
Step Temperature  Time (seconds) 
1. 95 °C 300 
2. 95 °C 30 
3. 40 °C  60 
4. 72 °C 60 
5. 72 °C 600 
6. 4 °C ∞ 
   
Step 2 to 4 were repeated for 50 cycles  
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2.10.3. Subcloning of PCR products 
The PCR products obtained from 2.10.2 were separated by Agarose-gel electrophoresis 
(2.7.2.) and extracted by using the GFX
TM
 System (Amersham) (2.7.2.). The purified 
fragments were sub-cloned into pCR2.1 vector (Topo TA cloning kit, Invitrogen) 
according to the manufactory’s instructions and transformed into chemical competent E. 
coli XL-1 blue cells (as mentioned for retransformation of plasmids in 2.1.3). On the next 
day, single bacteria colonies were picked and inoculated in 5 ml LB
+
 medium 
supplemented with ampicillin (100 µg/ml). After overnight incubation at 37ºC with 225 
rpm shaking, bacteria were harvested by centrifugation with 3600 rpm for 15 minutes at 4 
ºC. Thereafter, the plasmid-DNAs was isolated using the minipreparation of plasmid DNA 
by alkaline lysis with SDS (Sambrook & Russell, 2001). The following primer was used 
for sequencing.  
 
Primer name Sequence of primers  
M13 uni (-21) 5’- TGTAAAACGACGGCCAGT-3’ 
 
2.11. LDH assay 
The lactate dehydrogenase (LDH) assay is a colorimetric assay for the quantification of 
LDH that is released from the cytosol of damaged cells into the cell culture supernatant. 
Therefore, it can be used as cytotoxicity assay in the context of the effect of GCV on TK 
expressing ES cells. The LDH in cell culture supernatants was either directly analyzed 
using LDH assay or LDH was measured after complete lysis of cells of each set of samples: 
3x10
3
 ES cells transduced with NT, OT, CT and ST or untransduced (2.2.2) were seeded 
on a 24-well plate coated with a layer of feeder cells. One day after ES cell seeding, the 
medium was replaced by 500 µl fresh medium with 20 µM GCV. 36 hours later, further 
500 µl fresh medium with 20 µM GCV was added on the cells. Further 36 hours later (=72 
hours with GCV treatment), 50 µl of the supernatants from ES cells with GCV treatment 
and ES cells with GCV treatment after adding of lysis buffer for 15 minutes were each 
analyzed using the LDH assay in accordance to the manufacturer’s instructions. To obtain 
“background” signals feeder cells without ES cells were seeded as well and treated with 
GCV. 50 µl of the supernatants from feeder cells alone and feeder cells alone after adding 
of lysis buffer for 15 minutes were analyzed. These values with or without lysis were each 
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substracted from the extinction values obtained from ES cells. The differences between 
values with or without lysis represent the number of ES cells that survived GCV treatment. 
Extinction was each measured using ELISA reader (TECAN) with absorbance at 492 nm. 
 
2.12. in vivo experiments  
To investigate the fate of LV-TK-transduced ES cells in vivo, 100µl cell suspension with 
1x10
6
 untransduced ES cells, STPH-transduced ES cells with 1.5 copies per genome in 
average with hygromycin pre-selection or STPH-transduced ES cells with 3.8 copies per 
genome in average without hygromycin pre-selection (2.2.2) were injected into the hind 
limbs of Fox Chase SCID®  Beige mice (Charles River) (3.2.4). Three hours after ES cell 
injection, mice were administered with either saline solution (0.9% (w/v) NaCl) or GCV 
(20 mg/kg/day) for 12 days. Three weeks later, mice were sacrificed for the analysis of 
potential teratoma formation. The teratomas were analyzed by measuring their weight and 
size. For further analysis, teratomas were fixed in 4% (w/v) PFA in PBS, embedded in 
O.C.T. (Tissue-Tec) and stored at -80 °C. Sections were prepared in 10 µm thickness for 
H&E staining (see also 2.13). 
 
2.13. Hematoxylin and Eosin (H&E) staining  
H&E staining displays a common staining procedure to visualize structures of tissue. 
Hematoxylin solution is used for nuclei staining leading to visualization of nuclei in a blue 
color. Eosin stains the cytoplasm and connective tissue resulting in a variety of red or pink 
color. 
Teratomas sections (2.12.) were twice incubated in PBS for each 5 minutes. Afterwards, 
slides were treated with hematoxylin (Mayers hemalaun, Merck) for 1 minute and then 
washed in fluent water for 5 minutes. Thereafter, slides were stained with eosin (Eosin G 
supplemented with 0.5 % acetic acid, Merck) for 30 seconds and washed in fluent water 
for 5 minutes. Finally, slides were mounted with Roti® -Histokitt (Carl Roth). Images were 
taken using a AxioStart (Carl Zeiss) and AxioCam (Carl Zeiss). 
 
2.14. Immunochemistry  
Immunochemistry is a widely used method to detect specific antigens in cells or tissues by 
applying specific antibodies. The specific antigens are visualized by immunofluorescence 
resulting from antibodies conjugated to fluorescent dyes. 
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EBs (2.2.4.) were collected and washed twice with PBS. After that, EBs were incubated in 
Collagenase B (0.1 mg/ml, Roche) for 20 minutes in a shaker with 600 rpm at 37°C. 3x10
5
 
single cells from dissociated EBs were seeded per well of a 24-well plate with cover slips 
that were coated with gelatin (0.1% (w/v) in PBS). After reattaching of the cells on the 
cover slips (24 hours later), cells were fixed with 500 µl 4% (w/v) PFA at RT for 15 
minutes. The cover slips with fixed cells were removed from the 24-well plate and used for 
immunostaining: Therefore, they were incubated with primary antibodies in PBS solution 
containing 0.05% donkey serum (Jackson ImmunoResearch), 0.1% (v/v) triton, anti Oct-
3/4 (1:100, Santa Cruz Biotechnology) and anti α-actinin (1:400, Sigma-Aldrich) for 2 
hours. After removing the solution with the primary antibodies and washing three times 
with PBS, the cover slips were further incubated with secondary antibodies containing anti 
Dylight 549 and anti Dylight 649 (both 1:400, Jackson ImmunoResearch) in Hoechst stain 
solution (Sigma-Aldrich) for 1 hour. Images were taken using Axio Observer.Z1 with 
Apotome system (Clar Zeiss) and AxioCam MRC5 (Clar Zeiss). 
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3. Results  
3.1. Epigenetic regulation of LVs and RVs  
3.1.1. Viral vectors transduction of mouse embryonic stem cells (mixed populations) 
3.1.1.1. Viral vectors-transduced cells under undifferentiation conditions 
In order to compare the epigenetic regulation of LVs and RVs in murine ES cell 
populations, murine ES cells (R1 ES cell line) were transduced with VSV.G pseudotyped 
SIN-LV, SIN-RV and PCLMFG (MOI = 50) carrying each the eGFP reporter gene from 
the jellyfish Aequorea victoria driven either by an internal PGK promoter or by the 
wildtype 5’ LTR promoter (Figure 11) (see also 2.2.2). These ES cell populations were 
neither further selected after transduction nor further subcloned, but the whole populations 
including transduced and untransduced cells were used for analysis. Cell populations that 
were generated in this way are referred to as mixed populations in the following text.  
 
Figure 11: Constructs of SIN-LV, SIN-RV and PCLMFG carrying eGFP expressing cassette driven by 
internal PGK promoter or LTR promoter. PB: primer binding site; : packaging signal ; SD: splice donor; 
SA: splice acceptor; RRE: rev response element. 
After viral transduction, the ES cells were further cultured under undifferentiation 
conditions for 17 days and fluorescence images were taken. For quantification of eGFP 
expressing cells, flow cyctometry was applied. As the process of provirus integration, 
transcription and translation of the integrated transgene need approximately 48 hours, 
transgene expression was analyzed two days after virus transduction and additionally on 
day 17 post transduction. Images were each taken from undifferentiated ES cells that were 
transduced with the three vectors mentioned above (Figure 12). On day 17 post 
transduction, eGFP-positive cells were only observed in SIN-LV- and SIN-RV-transduced 
cells (Figure 12A). For quantification of eGFP-positive cells using flow cyctometry the 
“cut off” of the applied flow cytometer has to be set to 10% for untransduced (GFP 
negative) cells (Pfeifer & Hofmann, 2009). This means that 10% are equal to no eGFP 
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expression. Flow cyctometry analysis revealed more eGFP-positive cells (65.33±3.44%) 
on day 2 and on day 17 (59.28±4.88%) (Mean±SEM) for SIN-RV-transduced cells as 
compared to SIN-LV and PCLMFG, respectively (Figure 12B): SIN-LV-transduced cells 
resulted in 41.25±1.89% and 44.77±0.79% eGFP-positive cells on day 2 and 17 post 
transduction, whereas PCLMFG-transduced cells resulted in 38.36±10.51% eGFP-positive 
cells on day 2 post transduction and no eGFP expressing cells were detected on day 17 post 
transduction. A high reduction of eGFP-positive cells of PCLMFG-transduced cells to 
nearly the same level as untransduced cells (WT) was already observed on day 5 post 
transduction as analyzed by fluorescence microscopy (data not shown) as well as by flow 
cytometry. This indicates a strong silencing of integrated provirus DNAs in PCLMFG-
transduced ES cells under undifferentiation conditions. In contrast, SIN-LV and SIN-RV 
transduction resulted in a stable transgene expression in undifferentiated ES cells with 
overall a higher percentage of eGFP-positive cells for SIN-RV transduction.  
 
 
Figure 12: eGFP expression analysis of untransduced (WT) and SIN-LV-, SIN-RV- and PCLMFG-
transduced ES cells (mixed population, MOI=50) under undifferentiation conditions. (A) Brightfield 
and fluorescence images of untransduced (WT) ES cells or ES cells transduced by SIN-LV, SIN-RV and 
PCLMFG on day 2 and 17 post transduction. (B) Percentage of eGFP-positive ES cells as analyzed by flow 
cyctometry after viral transduction under undifferentiation conditions. Green rhombus: untransduced ES cells 
(WT). Red square: SIN-LV-transduced ES cells (SIN-LV). Black triangle: SIN-RV-transduced ES cells 
(SIN-RV). Blue circle: PCLMFG-transduced ES cells (PCLMFG) (n=3, Mean±SEM). 
 
3.1.1.2. Viral vectors-transduced cells under differentiation conditions 
In the next step, ES cells were transduced with the three viral vectors (Figure 11) and 
eGFP expression was analyzed under differentiation conditions. Therefore, untransduced 
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as well as transduced ES cells were cultured in suspension as aggregates (embryoid bodies 
(EBs) (Wobus & Boheler, 2005) (2.2.4). The EBs were either harvested on day 5 or 14 
post differentiation and eGFP-positive cells were detected by fluorescence microscopy and 
flow cyctometry. 
For PCLMFG-transduced cells, the eGFP-positive cells disappeared already on day 5 post 
differentiation (Figure 13A, B). In SIN-LV- and SIN-RV-transduced cells, very few eGFP-
positive cells were observed on day 5 post differentiation (Figure 13A upper) and nearly no 
eGFP-positive cell was detectable on day 14 post differentiation (Figure 13A lower). Flow 
cytometry analysis was consistent with the fluorescence images: The eGFP-positive cells 
of SIN-LV- and SIN-RV-transduced cells decreased dramatically from 41.25±1.89% and 
65.33±3.44% to 19.61±1.15% and 32.75±8.9% (Mean±SEM) on day 5 post differentiation, 
respectively (Figure 13B). Moreover, only 12.12±1.58% (SIN-LV) and 19.55±2.93% 
(SIN-RV) eGFP-positive cells were detected on day 14 post differentiation.  
 
Figure 13: eGFP expression of untransduced (WT) or SIN-LV-, SIN-RV- and PCLMFG-transduced 
ES cells (mixed population, MOI=50) under differentiation conditions. (A) Brightfield and fluorescence 
images of untransduced (WT) or ES cells transduced with SIN-LV, SIN-RV and PCLMFG on day 5 and 14 
post differentiation. (B). Percentage of eGFP-positive cells during 2-week differentiation after viral 
transduction. Green rhombus: untransduced ES cells (WT). Red square: SIN-LV-transduced ES cells (SIN-
LV). Black triangle: SIN-RV-transduced ES cells (SIN-RV). Blue circle: PCLMFG-transduced ES cells 
(PCLMFG) (n=3, Mean±SEM). 
Taken together, PCLMFG-mediated gene transfer led to complete silencing of the 
transgene in a mixed ES cell population already on day 2 post transduction under both 
undifferentiation or differentiation conditions. The SIN-LV- and SIN-RV-transduced 
mixed ES cell populations resulted in stable transgene expression for 17 days under 
undifferentiation conditions whereas the transgene expression in differentiated cells 
already declined on day 5 post differentiation. Epigenetic silencing of the transgene for 
Results 
55 
 
both SIN-LV and SIN-RV was obviously observed on day 14 post differentiation although 
a few eGFP-positive cells still remained in the SIN-RV-transduced cell population (Figure 
13). 
 
3.1.1.3. qPCR analysis of proviruses integration numbers 
In order to study whether the transgene expression is declining due to disappearing 
integrations of proviruses in undifferentiated or differentiated cell cultures, copy numbers 
of proviruses have been analyzed by using quantitative real-time PCR (qPCR). The loss in 
integration numbers can be due to overgrowing of infected cells by untransduced cells or 
due to the death of transduced cells. Thus, the gDNA of SIN-LV-, SIN-RV- and 
PCLMFG-transduced ES cells was isolated and used as templates for qPCR analysis, 
respectively. The quantifications of provirus integrations were each performed for 
undifferentiated as well as for differentiated cells (Figure 14). 
 
 
Figure 14: Copy number of provirus in SIN-LV-, SIN-RV- and PCLMFG-transduced ES cell s (mixed 
population, MOI=50) under undifferentiation (ES) and differentiation (EB) conditions. The copy 
numbers of the three viral vectors were analyzed by qPCR. Viral transduced ES cells were analyzed on day 2, 
5, and 17 post transduction and EBs were analyzed on day 5 and 14 post differentiation. As compared to ES 
d5 of each construct, copy numbers of ES d17, EB d5 and EB d14 show no significant difference, 
respectively (n=3, Mean±SEM, ANOVA, analysis of variance). 
In contrast to SIN-RV-transduced ES cells, SIN-LV- and PCLMFG-transduced ES cells 
contained on day 2 post transduction higher copy numbers of proviruses (7.04±3.42 and 
8.30±1.26 (Mean±SEM)) (Figure 14 left). The copy numbers immediately declined to less 
than 1 for both SIN-LV and PCLMFG vectors on day 5 post transduction (Figure 14 right). 
The already low copy number of the SIN-RV-transduced ES cell population was further 
reduced by around 30% to 0.64±0.19 from day 2 to 5 post transduction under 
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undifferentiation conditions (Figure 14). For all vector types these copy numbers then 
remain on approximately the same level until day 17 post transduction under 
undifferentiation conditions. ES cells were then differentiated into EBs and qPCR analysis 
was performed on day 5 and day 14 post differentiation. This also revealed no significant 
differences as compared to day 5 or day 17 post transduction under undifferentiation 
conditions.  
Different reasons are possible to explain the declining of provirus integration in the 
beginning. As reported by Butler et al (Butler et al, 2001), released proviruses in the 
cytoplasm after infection of host cells that were not integrated can form 1 or 2-LTR circle 
constructs within 24 hours post transduction. These LTR circles are also detected by qPCR 
but do not reveal from provirus integrations. Due to degradation of the LTR circles they 
can not be detected at later time points. As the SIN-LVs, SIN-RVs and PCLMFG vectors 
used are VSV.G pseudotyped they can transduce feeder cells as well, on which ES cells are 
seeded. Thus, transduction of these feeder cells also contributes to the copy numbers as 
determined by qPCR, although eGFP expression is only analyzed in ES cells. On day 5 
post transduction the feeder cells are replaced by fresh feeder cells when the ES cells are 
passaged. Therefore, the contribution of transduced feeder cells to the analyzed copy 
numbers has only be considered for provirus determination on day 2. Therefore, a 
comparison of the three vector types can only be performed on day 5 post transduction as 
well as on later time points.  
In conclusion, integration of provirus DNA is similar among the three vector types and 
therefore, this is not the reason for different eGFP expression patterns.  
 
3.1.1.4. Methylation analysis by using methylation-sensitive Southern blot method 
Early reports have proposed de novo methylation of the LTR promoter of MLV leading to 
transgene silencing during mouse embryogenesis (Challita & Kohn, 1994; Jahner et al, 
1982). DNA Methylation of provirus DNA has been also considered as a major reason of 
gene silencing in ES cells, originally in order to silence foreign DNA (Cherry et al, 2000). 
Methylation-sensitive Southern blot is a common method to detect the methylation state of 
integrated provirus DNA. Therefore, gDNAs of transduced ES cells and EBs were 
harvested on day 2, 5 and 17 post transduction and day 5 and 14 post differentiation. The 
gDNA was digested by two restriction enzymes involving a “methylation-insensitive” as 
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well as a “methylation-sensitive” enzyme (Figure 15). The methylation-sensitive enzyme 
can not digest cytosine-methylated fragments. By applying both enzyme types at the same 
time and analysis of the restriction pattern conclusions can be drawn concerning the 
methylation status of digested DNA.  
 
 
Figure 15: Schematic illustration of methylation-sensitive restriction.(A) methylation sensitive enzyme 
AscI is able to digest the unmethylated CpG DNA sequence. (B) Methylated CpG island sequence blocks the 
activity of AscI. 
 
Digesting the gDNA with the enzyme EcoRI and the methylation-sensitive enzyme AscI 
would result in a 1.8 kb fragment if SIN-LV provirus is methylated (Figure 16A). In case 
of unmethylated provirus SIN-LVs a 1.5 kb band would be found (Figure 16A). The 
restricted DNA is separated on an agarose gel and after blotting the bands can be targeted 
by a radioactive eGFP probe for visualization on a Southern blot (Figure 16B). On day 2, 5 
and 17 post transduction obviously only unmethylated bands of SIN-LV in undifferentiated 
ES cells were observed indicating no evidence of methylation (Figure16B, C). However, 
on day 5 and 14 post differentiation methylated bands were detected suggesting that the 
methylation of SIN-LV occurred in differentiated cells (Figure16B, C). 
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Figure 16: Analysis of the methylation status of SIN-LV proviruses using the methylation-sensitive 
restriction enzyme AscI. (A) DNA methylation of eGFP region was analyzed by digesting genomic DNA 
with EcoRI and methylation-sensitive enzyme AscI. Methylation of the CpG dinucleotide present in the AscI 
site results in a 1.8-kb band (I) in the Southern blot. Unmethylated DNA yields a 1.5-kb band (II) after 
EcoRI/AscI digestion. (B) Southern blot analysis of ES cells transduced with SIN-LVs on day 2, 5 and 14 
post transduction and EBs on day 5 and 14 post differentiation. Radioactive labeled eGFP probe was used to 
detect digested fragments. (C) The methylation status of integrated proviruses were quantified by calculating 
the ratio of methylated band (I) to unmethylated band (II) using Quantity One 1-D Analysis Software (Bio-
Rad) (n=3, Mean±SEM).  
 
For the analysis of the methylation status inSIN-RV-transduced ES cells the methylation-
sensitive enzyme SalI was used as well as the methylation-insensitive enzyme Acc65I. This 
results in a 2.6 kb methylated band (I) in methylated SIN-RV proviruses and a 1.8 kb 
unmethylated band (II) in unmethylated SIN-RV proviruses (Figure 17A). In comparison 
to SIN-LVs, weak methylated bands were already observed in undifferentiatedSIN-RV-
transduced ES cells (Figure 17B, C). Moreover, methylated bands obviously appeared on 
day 5 and 14 in EBs indicating apparently a methylation of SIN-RV proviruses under 
differentiation condition (Figure 17B, C).  
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Figure 17: Analysis of the methylation status of SIN-RV proviruses using the methylation-sensitive 
restriction enzyme SalI. (A) DNA methylation of eGFP region was analyzed by digesting gDNA with 
Acc65I and methylation-sensitive enzyme SalI. Methylation of the CpG dinucleotide present in the AscI site 
results in a 2.6-kb band (I) in the Southern blot. Unmethylated DNA yields a 1.8-kb band (II) after 
Acc65I/SalI digestion. (B) Southern blot analysis of ES cells transduced with SIN-RVs on day 2, 5 and 14 
post transduction and EBs on day 5 and 14 post differentiation. Radioactive labeled eGFP probe was used to 
detect digested fragments. (C) The methylation status of integrated proviruses were quantified by calculating 
the ratio of methylated band (I) to unmethylated band (II) using Quantity One 1-D Analysis Software (Bio-
Rad) (n=3, Mean±SEM). 
In summary, methylation levels are extremely low at undifferentiation stage of both SIN-
LV- and SIN-RV-transduced ES cells (Figure 16C and 17C). The methylation occurred 
firstly on day 5 post differentiation, and is even stronger on day 14 post differentiation. 
The correlations between eGFP-positive cells and methylation level are displayed in a 
diagram (Figure 18). This reveals strong inverse correlations between the methylation 
coefficient and the percentage of eGFP-positive cells for both SIN-LV and SIN-RV 
(Figure 18) and indicates that lower eGFP expression rates indeed are the consequence of 
provirus methylation. Interestingly, this is true for both vector types analyzed under 
undifferentiation as well as under differentiation conditions.  
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Figure 18: Correlation between percentage of eGFP-positive cells and methylation coefficient. The 
methylation level of SIN-LV (hollow circles) and SIN-RV (solid circles) proviruses in transduced ES cells 
were compared to percentage of eGFP-positive cells under undifferentiation and differentiation conditions 
(Data are obtained from Figures 12B, 13B, 16C and 17C) 
 
3.1.2. Single copy clones of SIN-LV- and SIN-RV-transduced ES cells 
3.1.2.1. Generation of single copy SIN-LV and SIN-RV ES cell clones 
As figured out, methylation plays an important role in epigenetic regulation of SIN-LV and 
SIN-RV in mixed ES cell populations (see also Figure 18). For a more accurate analysis of 
SIN-LV and SIN-RV mediated gene expression single copy ES cell clones were generated 
instead of the use of mixed cell populations analyzed so far. Therefore, ES cell were 
transduced with SIN-LV and SIN-RV and single clones were picked. The gDNAs from 
picked cell clones were subsequently isolated, digested by BamHI enzymes and finally 
screened by using Southern blot analysis to obtain ES cell clones with single integrant 
(Figure 19).  
For the following analysis of eGFP expression, SIN-LV and SIN-RV ES cell clones with 
only one integrant were chosen, that were identified by Southern blot analysis (SIN-LV: 
#40 and #52; SIN-RV: #10 and #14) (Figure 19). 
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Figure 19: gDNA digestion of picked cell clones from SIN-LV- and SIN-RV-transduced ES cells and 
Southern blot analysis. ES cells were transduced with SIN-LVs (A) or SIN-RVs (B), clones were picked, 
expanded and gDNA was isolated and digested with BamHI. Southern blot analysis was used to detect the 
number of provirus integrations. Marked by an arrow are single copy SIN-LV ES cell clones #40 (3 kb) and 
#52 (1.8 kb)(A) and single copy SIN-RV ES cell clones #10 (7 kb) and #14 (12 kb) (B). 
Quantification using flow cyctometry revealed that for both constructs the ES cell clones 
showed either low or high eGFP expression levels, respectively (Figure 20). Theses single 
copy ES cell clones were chosen for further investigations.  
 
Figure 20: Mean fluorescence intensity (MFI) of single copy ES cell clones. ES cell clones with single 
integrant were identified by Southern blot analysis. eGFP expression levels were analyzed by flow 
cyctometry. SIN-LV ES cell clones #40 (LV #40) and #52 (LV #52) express low and high levels of eGFP, 
respectively; SIN-RV ES cell clones #10 (RV #10) and #14 (RV #14) are express low and high levels of 
eGFP, respectively (n=3, Mean±SEM). 
 
3.1.2.2. Single copy ES cell clones under undifferentiation conditions 
The four ES cell clones obtained from picked clones (3.1.2.1) were then cultured under 
undifferentiation conditions for 15 days and eGFP expression was analyzed every three 
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days. As shown on Figure 20, clones LV #40 and RV #10 expressed low eGFP levels.  
This could also be seen under undifferentiation conditions as analyzed by fluorescence 
microscopy (Figure 21A upper). High eGFP level expressing clones LV #52 and RV#14 
(see also Figure 20) showed also high levels of eGFP-positive cells on day 3 post plating 
under undifferentiation conditions (Figure 21A upper). On 15 day post plating, high eGFP 
level expressing clones LV #52 and RV#14 still showed the high eGFP expressions and for 
LV #40 and RV #10 the same slight eGFP expressions as seen on day 3 were observed on 
day 15 post plating (Figure 21A lower). All four ES cell clones revealed a stable eGFP 
expression under undifferentiation conditions as also quantified by using flow cytometry 
(Figure 21B). 
 
Figure 21: eGFP expression of single copy ES cell clones under undifferentiation conditions. (A) 
Brightfield and fluorescence images of untransduced (WT) ES cells and SIN-LV- and SIN-RV-transduced 
ES cell clones carrying a single integrant on day 3 and 15 post plating. (B) Percentage of eGFP-positive ES 
cells during cultivation under undifferentiation conditions for 15 days. Green rhombus: untransduced ES cells 
(WT). Black triangle: SIN-LV ES cell clone #40 (LV #40). Purple rhombus: SIN-LV ES cell clone 52 (LV 
#52). Red circle: SIN-RV ES cell clone #10 (RV #10). White square: SIN-RV ES cell clone #14 (RV #14) 
(n=3, Mean±SEM). 
 
3.1.2.3. Single copy ES cell clones under differentiation conditions 
Next, the single integrant ES cell clones were cultured under differentiation conditions and 
analyzed by fluorescence microscopy and flow cyctometry on day 5 and 14 post 
differentiation. eGFP expressions of the two low expressing cell clones (LV #40 and RV 
#10) could not be detected on day 5 and 14 post differentiation in fluorescence images 
(Figure 22A) and percentages of eGFP-positive cells decreased from around 80% to less 
than 20% on day 5 post differentiation. On day 14 post differentiation the percentages of 
eGFP-positive cells of these two clones  were on the similar level as untransduced cells 
(WT) (Figure 22B) as already seen on fluorescence images (see also Figure 22A ). 
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In contrast, eGFP expressions of high expressing LV #52 and RV #14 clones were still 
detectable in the fluorescence images on day 5 post differentiation (Figure 22A). Flow 
cytometer revealed 74.30±9.69% and 55.61±11.20% eGFP positive cells on day 5 post 
differentiation and still 50.21±4.18 and 40.32±3.22 % eGFP positive cells on day 14 post 
differentiation for clones LV #52 and RV #14, respectively (Figure 22B). In addition, the 
high eGFP expressing RV #14 clone showed a higher reduction of eGFP-positive cells as 
compared to LV #52 (Figure 22B).  
 
Figure 22: eGFP expression of single copy ES cell clones under differentiation conditions. (A) 
Brightfield and fluorescence images of EBs on day 5, 14 post differentiation of untransduced (WT) ES cells 
and SIN-LV- and SIN-RV-transduced ES cell clones carrying a single integrant. (B) Percentage of eGFP-
positive cells during 2-week differentiation. Green rhombus: untransduced ES cells (WT). Black triangle: 
SIN-LV ES cell clone #40 (LV #40). Purple rhombus: SIN-LV ES cell clone 52 (LV #52). Red circle: SIN-
RV ES cell clone #10 (RV #10). White square: SIN-RV ES cell clone #14 (RV #14) (n=3, Mean±SEM). (C) 
Brightfield and fluorescence images of EBs of untransduced (WT) ES cells and SIN-LV- and SIN-RV-
transduced ES single copy clones on day14 post differentiation with 5’Aza treatment. 
As already shown for mixed ES cell populations, the methylation status of provirus 
integration had a high impact on transgene silencing (see also Figure 18). Therefore, an 
inhibitor against DNA methyltransferases was applied in order to prevent methylation of 
integrated provirus DNA during differentiation. The inhibitor (5-aza-2’ deoxycytidine (5’-
Aza)) was applied on day 11 post differentiation on the cells and fluorescence images were 
taken three days later (Figure 22C). Unexpectedly, the 5’-Aza was not able to reactive the 
eGFP expression in these four ES cell clones. 
When comparing images of eGFP fluorescence and percentage of eGFP-positive cells it 
can be clearly seen that intensity of eGFP expression is much higher for LV #52 as for RV 
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#14, although the number of transduced cells were both in a similar range. Therefore, in 
the next step, the eGFP intensity was also quantified (Figure 23): The two low expressing 
clones (LV #40 and RV #10) show a declining in eGFP intensity to WT level already 
within the first five days post differentiation. Although the high eGFP expressing RV #14 
clone resulted in more than 50% eGFP-positive cells (see Figure 22B), the eGFP intensity 
decreased rapidly to a very lower level (Figure 23). In contrast to RV #14, the high eGFP 
expressing ES cell clone LV #52 showed a much lower decreasing in eGFP intensity 
although the intensity on day 0 (before differentiation) was lower as compared to RV #14 
(Figure 23). Taken together, the ES cell clone LV #52 had the highest level of eGFP 
expression as observed on fluorescence images and by measuring the mean fluorescence 
intensity and also revealed the highest percentage of eGFP expressing cells under 
differentiation conditions. 
 
Figure 23: Mean fluorescence intensity (MFI) of single copy ES cell clones during 2-week 
differentiation. Green rhombus: untransduced ES cells (WT). Black triangle: SIN-LV ES cell clone #40 (LV 
#40). Purple rhombus: SIN-LV ES cell clone 52 (LV #52). Red circle: SIN-RV ES cell clone #10 (RV #10). 
White square: SIN-RV ES cell clone #14 (RV #14) (n=3, Mean±SEM). 
 
3.1.2.4. Methylation-sensitive Southern blot analysis 
To identify the reason for the decrease in eGFP intensity the methylation status of 
integrated provirus DNA was next investigated. Therefore, the four single copy ES cell 
clones were studied by using methylation-sensitive Southern blot analysis as already 
applied for the mixed ES cell populations. The four ES cell clones were cultured under 
undifferentiation conditions for 15 days and in parallel under differentiation conditions for 
14 days. The gDNAs of LV clones #40 and #52 were each digested by EcoRI and AscI 
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(methylation sensitive enzyme) leading to unmethylated (1.5 kb) and methylated bands 
(1.8 kb) (Figure 24A, B) and analyzed by Southern blot. 
 
 
Figure 24: Analysis of the methylation status of SIN-LV ES cell clones using the methylation-sensitive 
restriction enzyme AscI. (A) Methylation of the eGFP region was analyzed by digesting gDNA with the 
methylation-sensitive AscI. Methylation of the CpG dinucleotide present in the AscI site results in a 1.8-kb 
band in the Southern blot (band I). Unmethylated DNA yields a 1.5-kb band after EcoRI/AscI digestion (band 
II). (B) Southern blot analysis of single copy ES cell clones SIN-LV #40 and #52 on day 0, 3 and 15 post 
plating and EBs on day 5 and 14 post differentiation. Radioactive labeled eGFP probe was used to detect 
digested fragments. (C) The methylation status of integrants were quantified by calculating the ratio of 
methylated (band I) to unmethylated bands (band II) (n=3, Mean±SEM). 
The low eGFP expressing ES cell clone LV #40 showed mainly unmethylated bands under 
undifferentiation conditions (ES cells on day 0, 3 and 15 post plating) whereas only very 
weak methylated bands were observed (Figure 24B left). Under differentiation conditions 
(EBs on day 5 and 14 post differentiation) very strong methylated bands were observed 
and only weak unmethylated bands (Figure 24B left). In contrast, the eGFP high 
expressing ES cell clone LV #52 showed clearly unmethylated bands under both 
undifferentiation and differentiation conditions and under differentiation conditions (EBs 
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on day 5 and 14 post differentiation) only slight methylated bands were detected (Figure 
24B right). 
Taken together, these results indicate that the eGFP low expressing LV #40 had just a 
slight methylation before differentiation and a high methylation level during the 
differentiation. The provirus DNA of high expressing clone LV #52 maintained the 
unmethylation state until the end of the differentiation process. Taking the intensities of 
methylated and unmethylated bands into account it is clearly visible that   LV #40 clone 
shows a much stronger methylation after differentiation (Figure 24B, C left). In contrast, 
ES cell clone LV #52 revealed a much slighter methylation under differentiation conditions 
(Figure 24 B, C right).  
Next, the methylation status of low and high expressing RV ES cell clones #10 and # 14 
were also analyzed by methylation–sensitive Southern blot using Acc65I and SalI 
(methylation-sensitive enzyme) resulting in 2.6 kb (methylated) and 1.8 kb (unmethylated) 
bands (Figure 25A). The low eGFP expressing RV ES cell clone #10 showed only very 
weak unmethylated bands and mainly strong methylated bands under undifferentiation 
conditions (ES cells on day 0, 3 and 15 post plating) (Figure 25B left). Furthermore, under 
differentiation conditions (EB on day 5 and 14 post differentiation) the methylated bands 
of RV #10 were even stronger indicating a very high methylation level (Figure 25B left). 
In contrast, the high eGFP expressing RV ES cell clone #14 revealed obviously 
unmethylated bands only under undifferentiation conditions whereas methylated bands are 
mainly visible at differentiation stage (Figure 25 right). This suggests that a high 
methylation level of RV #14 occurs notably during the differentiation. Again, by 
quantifying intensity of unmethylated and methylated bands a high methylation has been 
obtained in RV #10 in both undifferentiation and differentiation stages (Figure 25C left). 
On the other hand, a high methylation was only observed in RV #14 under differentiation 
conditions (Figure 25C right). 
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Figure 25: Analysis of the methylation status of SIN-RV ES cell clones using the methylation-sensitive 
restriction enzyme SalI. Methylation of the eGFP region was analyzed by digesting gDNA with the 
methylation-sensitive SalI. Methylation of the CpG dinucleotide present in the SalI site results in a 2.6-kb 
band after Acc65I/SalI digestion (band I). Unmethylated DNA yields a 1.8-kb band in the Southern blot 
(band II). (B) Southern blot analysis of single copy ES cell clones SIN-RV #10 and #14 on day 0, 3 and 15 
post plating and EBs on day 5 and 14 post differentiation. Radioactive labeled eGFP probe was used to detect 
digested fragments. (C) The methylation status of integrants were quantified by calculating the ratio of 
methylated (band I) to unmethylated bands (band II) (n=3, Mean±SEM). 
 
Next, the percentages of eGFP positive cells (see also Figures 21B and 22B) were 
correlated to the coefficients of methylation (see also Figures 24C and 25C) for the four 
different single integrated ES cell clones (Figure 26) for both undifferentiation and 
differentiation conditions. An inverse correlation between eGFP-positive cells and 
methylation coefficient has been observed for both low and high eGFP expressing LV ES 
cell clones (Figure 26A). The same is true for high eGFP expressing RV ES cell clone #14 
(Figure 26B). In contrast, a lower correlation coefficient was obtained for low expressing 
clone RV #10 (Figure 26B). This may be due to the fact that already a very high 
methylation level was observed under undifferentiation conditions for RV#10. 
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Figure 26: Correlation between percentage of eGFP-positive cells and methylation levels in the eGFP 
region of SIN-LV and SIN-RV ES cell clones. (A) Comparison of SIN-LV ES cell clones: LV #40 (low) vs. 
LV #52 (high). (B) Comparison of SIN-RV ES cell clones: RV #10 (low) vs. RV #14 (high) (C) Comparison 
between high eGFP expressing clones: LV #52 vs. RV #14. (D) Comparison of low eGFP expressing clones: 
LV #40 vs. RV #10. Data were obtained from Figures 21B, 22B, 24C and 25C. 
Comparing high eGFP expressing ES cell clone LV #52 with its retroviral counterpart (RV 
#14) shows a lower slope of the regression curve for RV#14 (Figure 26C) indicating a 
higher methylation level as already seen on methylation sensitive southern blot (see also 
Figures 24C and 25C, right). Taking the fluorescence images (Figure 22A) and the mean 
fluorescence intensities (Figure 23) into account, a clear relation between methylation 
pattern and transgene silencing can be drawn as e.g. clone LV#52 also showed high eGFP 
expression under both differentiation and undifferentiation conditions. This indicates that 
methylation plays an important role on high eGFP expressing clones. In contrast, both low 
eGFP expressing ES cell clones (LV#40, RV#10) show different levels of methylation on 
undifferentiation and differentiation stage with no particular difference among the two 
clones (Figure 26D). Compared to the high expressing clones a generally higher 
methylation level can be observed (see also Figures 24C and 25C). This is also reflected in 
the low eGFP expressions (see also Figures 21 and 22). 
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Taken together, the methylation mechanisms indeed dramatically reduce the transgene 
expressions.  
 
3.1.2.5. Methylation analysis by bisulfite sequencing 
Besides methylation-sensitive Southern blot analysis, bisulfite sequencing represents a 
versatile approach for a more precise methylation analysis (Hayatsu et al, 1970; Laird, 
2003)  (2.10). Therefore, DNA is treated with bisulfite, amplified by PCR and the PCR 
products are subcloned for subsequent sequencing. Bisulfite treatment leads to conversion 
of unmethylated cytosines of DNAs into uracil whereas methylated cytosines can not be 
affected (Figure 27). During PCR, uracils are amplified as thymidines and the unaffected 
methylated cytosines are amplified again as cytosines (Figure 27). After subcloning of the 
amplified fragments in plasmids, the DNA is sequenced and compared to the sequence of 
untreated DNA. The methylation levels can then be evaluated by the percentage of 
methylated cytosines as compared to unmethylated ones. 
 
Figure 27: Schematic illustration of bisulfite sequencing. DNA is treated with sodium bisulfite solution 
resulting in conversion of unmethylated cytosine to uracil whereas 5-Methyl-cytsoine is not affected. PCR 
amplication results finally in replacement of uracil to thymidine and replacement of methylated cytosine to 
cytosine. 
The four single copy LV and RV ES cell clones (LV #40, LV #52, RV #10, RV #14) were 
cultured under differentiation conditions for 14 days and the EBs on day 14 post 
differentiation were used for gDNA isolation. After bisulfite conversions of gDNAs, the 
eGFP region (255 bp) containing 18 CpG islands was amplified by using non-methylation 
primers (Laird, 2003) and the resulting PCR products were subcloned into plasmids. Figure 
28 shows the sequencing results of several plasmids that were finally obtained from the ES 
cell clones with one row representing the 18 CpG islands, respectively. Several rows for 
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one clone show different plasmids that were used for sequencing. Closed circles indicate 
methylated CpGs, open circles indicate unmethylated CpGs. Except for one plasmid of low 
expressing clone LV #40, all plasmids demonstrated almost complete methylation of CpG 
islands with an average CpG methylation of 78.89±16.51% (n=6, Mean±SEM). In contrast, 
only the half of CpG islands in high expressing LV #52 was methylated (53.33±17.18%, 
n=4, Mean±SEM). Interestingly, both low and high expressing RV ES cell clones (#10 and 
#14) showed a high methylation level of CpG islands (94.44±2.97% and 88.89±3.93%, 
n=7 and n=4, Mean±SEM, respectively) indicating an almost complete methylation under 
differentiation conditions for both clones. 
 
Figure 28: High-resolution DNA methylation analysis of CpG dinucleotides of the eGFP gene by 
bisulfite sequencing. Methylation pattern of a 255-bp region (18 CpG islands) in the eGFP region of SIN-
LV clones (left) and SIN-RV clones (right). Low expressing LV #40 exhibits 78.89±16.51% (n=6) CpG 
methylations. High expressing LV #52 53.33±17.18%, (n=4) CpG methylations. Low expressing RV #10 
exhibits 94.44±2.97% (n=7) CpG methylations. High expressing RV #52 exhibits 88.89±3.93% (n=4) CpG 
methylations. Closed circles indicate methylated CpGs, open circles indicate unmethylated CpGs. 
(Mean±SEM). (2.10) 
 
The bisulfite sequencing results of the four clones corresponds nicely with the results 
obtained from the methylation-sensitive Southern blot analyses of differentiated clones 
(see also Figures 24C and 25C): these quantifications revealed a methylation ratio of:4:1 
(=80% methylation) for low eGFP expressing LV #40, 1:1 (=50% methylation) for high 
eGFP expressing LV #52, 15:1 (=93% methylation) for low eGFP expressing RV #10) and 
15:1 (=93% methylation) for high eGFP expressing RV #14. 
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3.1.3 SIN-LV and SIN-RV transgenic mouse  
Finally, transgenic mice were generated to study the eGFP expression in vivo when using 
SIN-LVs or SIN-RVs. For transgenesis, the subzonal virus injection method was used in 
which the viral vectors are directly injected in the perivitelline space of fertilized oocytes 
(Figure 29) (Fassler, 2004; Hofmann et al, 2004). The injected zygotes were further 
incubated until reaching morulae or blastocyst state and were then transferred into 
pseudopregnant foster mice. 
Around 10 to 20 embryos were used for transfer into the uterus of one foster animal. 
Around two weeks after the uterine transfer pups were born. These pups were further 
screened by using genotyping PCR and Western blot analysis for detection of viral 
integration and eGFP expression, respectively. 
 
 
Figure 29: Subzonal virus injection of embryos. The schematic illustration was modified from Faessler, 
2004 (Fassler, 2004) and shows the procedure of generation of transgenic mice by injection of viral vectors 
into the perivitelline space through the zona pellucida of a fertilized oocyte. 
. 
gDNA for genotyping PCR was isolated from pup’s tail and specific eGFP primers were 
chosen to amplify the eGFP region of integrated proviruses. PKG-1 primers were used as 
loading control of gDNA (Figure 30A) (2.6.1). In order to check whether these integrated 
proviruses also express eGFP protein, Western blot analysis of proteins, isolated from 
pup’s tail, was used by applying eGFP antibody and β-actin antibody as loading control, 
respectively (Figure 30B).  
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Figure 30: Analysis of newborn mice generated by subzonal virus injection of embryos by genotyping 
PCR and Western blot. The tail end of pups resulting from subzonal injection of SIN-LVs or SIN-RVs was 
used for gDNA and protein isolation and further analyzed using PCR or Western blot, respectively. (A) PCR 
using GFP primers was applied to detect cDNA of GFP from integrated provirus in SIN-LV/RV transgenic 
mice leading to a 716 bp band. AP18 and KISAX primers were used as PCR loading control targeting the 
housekeeping gene Protein Kinase G 1 (PKG-1) leading to a 529 bp band. (B) Western blot analysis using 
GFP antibody resulted in a 55 kD band and β-actin antibody was used as loading control resulting in a 42 kD 
band. Gels and blots are representative examples; at least PCR analysis was performed for all pups, Western 
blot analysis was done for proteins of all transgenic pups. 
Performing two subzonal SIN-LVs injections thirteen pups were born from eight foster 
animals (Table 2). Six out of the thirteen pups were transgenic as shown by PCR analysis 
(Figure 30A left, only transgenic pups are shown, Table 2). All of these six SIN-LV 
transgenic mice showed eGFP expression as analyzed using Western blot (Figure 30B left, 
Table 2). In contrast, from nine subzonal SIN-RVs injections only two out of fifty three 
pups born were transgenic as proven by PCR analysis (Figure 30A right, Table 2). 
Interestingly, both transgenic mice showed no eGFP expression (see also Figure 30B right; 
one of the two transgenic mice is shown).  
Table 2: Summary of transgenic mice generated by subzonal injections.  
Virus 
numbers 
of SI's  
number of 
fosters 
number of injected 
embryos 
sum 
pups 
transgenic 
pups (PCR) 
GFP positive 
pups (WB) 
SIN-LV 2 8 71 13 6 6 
SIN-RV 9 33 438 53 2 0 
 
Taken together, the efficiency in generation of transgenic mice by applying subzonal 
injection is much higher for SIN-LVs as compared to SIN-RVs (Figure 31). In addition, all 
of the transgenic mice resulting from SIN-LV injection revealed eGFP expression. In 
contrast, SIN-RV injection showed not only low efficiency in generating transgenic pups 
but also resulted in no eGFP expressing mouse (Figure 31).  
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Figure 31: Statistic analysis of SIN-LV and SIN-RV gene transfer in mice. Data were used from Table 2. 
 
Another part of the present work beside the analysis of the epigenetic regulation of SIN-
RVs and SIN-LVs in ES cells was the application of SIN-LVs for efficient transgene 
expression for an approach in regenerative medicine. 
 
3.2. LVs-mediated TK expression in pluripotent stem cells for regenerative medicine 
In the second part of this work, the focus relied on the specific elimination of pluripotent 
stem cells. Cell populations that were differentiated from pluripotent stem cells carry a 
potential risk of tumor formation due to the contamination with residual undifferentiated 
cells. Therefore, the HSV-TK/GCV system was applied on pluripotent stem cells in order 
to remove potential tumor-forming cells. The system relies on expression of the suicide 
gene thymidine kinase (TK, from Herpes simplex virus) that converts the prodrug 
Ganciclovir (GCV) into a toxic metabolite leading to cell death. For the genetic 
modification of cells, SIN-LVs were chosen as a gene transfer tool to mediate TK 
expression. For this purpose the  murine ES cell line α-pig was used which carries the 
genes for puromycin resistance and green fluorescence protein (eGFP) connected via the 
IRES (internal ribosomal entry site) element under control of the cardiac specific α-myosin 
heavy chain (α-MHC) promoter (Figure 32). This leads to transgene expression only in ES 
cell-derived cardiomyocytes (Kolossov et al, 2005). Within the context of in vitro ES cell 
transduction two different approaches were applied: lentiviral transduction of ES cells and 
GCV treatment of these mixed cell populations without further selection or picking of ES 
cell clones that were used for further treatment and analysis.  
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Figure 32: Schematic drawing of transgene cassette of ES cell line used (α-pig ES cells). Murine ES cells 
(D3 cell line) carry the expression cassette for puromycin resistance connected with eGFP gene via an IRES 
(internal ribosomal entry site) element driven by mouse cardiac specific α-myosin heavy chain (α-MHC) 
promoter..  
 
3.2.1. LVs-mediated TK expression in ES cells 
In order to generate ES cells stably expressing TK, LVs carrying HSV-TK cDNA under 
the control of the promoter of pluripotency genes Nanog or Oct-3/4 (NT and OT) (Figure 
33A) were applied leading to TK expression only in undifferentiated ES cells (Chambers et 
al, 2003; Mitsui et al, 2003; Niwa et al, 2000; Ovitt & Scholer, 1998). Treatment of the 
transduced cells with GCV for 72 hours had a high killing effect on the ES cells under 
undifferentiation conditions (Figure 33B). Using different concentrations of GCV in 
preliminary experiments revealed that treatment with 20 µM GCV was sufficient to 
eliminate undifferentiated cells in mixed ES cell populations. Moreover, higher GCV 
concentrations led to cellular toxicity to untransduced ES cells (Figure 33B). Therefore, 20 
µM GCV was used in all further in vitro experiments.  
 
Figure 33: Constructs of SIN-LVs carrying TK expression cassette and analysis of NT- or OT-
transduced ES cells in vitro. (A) Constructs of LVs carrying thymidine kinase gene from herpes simplex 
virus driven by pluripotent promoter Nanog (NT) or Oct-3/4 (OT). (B) ES cells were transduced with LVs 
(NT and OT, 200 ng of reverse transcriptase) or not transduced (WT) and further treated with 0, 10, 20, 40, 
60, 80 and 100 µM GCV for 72 hours. Representative brightfield images are shown (n=3).  
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Next, the effect of GCV in LV-transduced ES cells under differentiation conditions was 
investigated. For differentiation, untransduced (WT) and NT- or OT-transduced ES cells 
were cultured as embryoid bodies (EBs) by using the mass culture protocol (Doetschman 
et al, 1985) for 14 days. If EBs contained ES cell-derived cardiomyocytes, eGFP 
expressions driven by cardiac specific promoter α-MHC were detectable using 
fluorescence microscopy (Figure 34A). Fluorescence images of untransduced and NT- or 
OT-transduced EBs (with or without 20µM GCV treatment) revealed eGFP expression, 
respectively indicating formations of ES cell-derived cardiomyocytes in EBs (Figure 34B). 
 
Figure 34: Differentiation of untransduced (WT) and NT- or OT-transduced ES cells. (A) Schematic 
representation of the strategy to detect the formation of cardiomyocytes by eGFP expression (modified form 
Ieda et al, 2010). (B) Brightfield and fluorescence images of EBs derived from untransduced (WT) and NT- 
or OT-transduced ES cells on day 14 post differentiation. eGFP expression driven by cardiac specific 
promoter α-MHC indicates formation of ES cell-derived cardiomyocytes. 
The resulting EBs were further dissociated and characterized by immunostaining with 
antibodies against Oct-3/4 (ES cell marker) and Hoechst (nucleus staining) (Figure 35A). 
By counting of Oct-3/4-positive cells without GCV treatment, 21.76%±1.27, 21.14%±2.39 
and 22.12%±2.07 (Mean±SEM) Oct-3/4-positive cells were observed in the untransduced 
and NT- or OT-transduced ES cells, respectively, indicating that these cells remained 
undifferentiated and maintained their pluripotent status (Figure 35B). In the untransduced 
ES cells with GCV treatment, 20.95%±1.96 Oct-3/4-positive cells were observed 
indicating that GCV alone had no influence on the vitality of the cells (Figure 35B). In 
contrast, only 4.68%±1.36 and 3.75%±2.24 (Mean±SEM) of the NT- or OT-transduced ES 
cells were quantified as Oct-3/4-positive when treated with GCV (Figure 35B). Thus, most 
of the undifferentiated ES cells were eliminated during differentiation by TK mediated 
GCV conversion leading to cell death. Neither the LV transduction nor the GCV treatment 
alone influenced differentiation of ES cells (Figure 35B). 
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Figure 35: Analysis of dissociated EBs derived from untransduced (WT) and NT- or OT-transduced 
ES cells using immunochemistry. (A) NT- or OT-transduced ES cells and untransduced (WT) ES cells (+/- 
GCV) were differentiated and immunostaining of dissociated EBs on day 14 with Oct-3/4 (red) and Hoechst 
(blue) was performed indicating undifferentiated ES cells and nucleus, respectively. Representative images 
are shown (n=3). (B) Percentage of Oct-3/4-positive cells on day 14 post differentiation analyzed by cell 
counting of images representatively shown in (A) (n=5, Mean±SEM, ***P<0.001, ANOVA, analysis of 
variance).  
Immunostaining of the dissociated EBs using antibody against α-actinin (sarcomere marker) 
showed that untransduced (WT) as well as the transduced ES cells (NT and OT) were able 
to differentiate into ES cell-derived cardiomyocytes as also shown by cardiac-specific α-
MHC promoter driven eGFP expression (Figure 36). 
 
Figure 36: Immunostaining of dissociated EBs derived from untransduced (WT) and NT- or OT-
transduced ES cells. Immunostaining of dissociated EBs on day 14 post differentiation with antibody 
against skeletal α-actinin (sarcomere) indicating the formation of ES cell-derived cardiomyocytes (white); 
green fluorescence indicates eGFP expression driven by cardiac specific promoter, α-MHC. 
 
3.2.2. LVs-mediated TK expression in induced pluripotent stem (iPS) cells 
Like ES cells, iPS cells also carry the potential risk of tumor formation in in vivo 
applications. Thus, removal of iPS cells that did not undergo differentiation is an important 
task which could bring iPS cells closer to clinical applications. The LVs NT and OT 
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(Figure 33A) were applied on two different iPS cell lines: iPS and iPS-Oct-GFP, the latter 
containing an eGFP expression cassette under the control of the pluripotent Oct-3/4 
promoter. Upon GCV administration, almost no survival of NT- or OT-transduced iPS-
cells could be observed under undifferentiation conditions (Figure 37A).  
 
Figure 37: Analysis of NT- or OT-transduced iPS cells in vitro. (A) iPS cells were transduced with LVs 
(NT and OT, 300 ng of reverse transcriptase) or not transduced (WT) and further treated without/with (-/+) 
20 µM GCV under undifferentiation conditions. Representative brightfield images are shown (n=3). (B) iPS-
Oct-GFP cells were transduced by NT and OT (300 ng of reverse transcriptase) or not transduced (WT) and 
treated without/with (-/+) 20 µM GCV under undifferentiation conditions. Representative brightfield and 
fluorescence images are shown (n=3).  
Brightfield and fluorescence images of iPS-Oct-GFP cells also revealed a high killing 
effect of the TK/GCV system on these cells as no eGFP-positive cells survived in the NT- 
or OT-transduced cells upon GCV treatment (Figure 37B). Taken together, besides murine 
ES cells, the TK/GCV system also led to an efficient elimination of undifferentiated iPS 
cells upon GCV treatment in vitro. Further experiments using iPS cells were not performed 
within the present study. 
 
3.2.3. LVs-mediated TK expression in ES cells with low copy numbers  
3.2.3.1 NT- or OT-transduced mixed ES cell populations 
The initial experiments clearly demonstrated the usability of the TK/GCV system in 
pluripotent stem cells. In these experiments LVs with a certain physical titer (displayed as 
ng reverse transcriptase per µl) were used. However, for clinical applications, it is 
worthwhile to use low copy numbers of LVs to minimize the potential risk of insertional 
mutagenesis by LV integrations (Zielske et al, 2004). Therefore, ES cell populations with a 
low average copy number of approximately 1.5 provirus integrations per genome were 
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investigated. Recent reports showed that quantitative real time PCR (qPCR) can be used as 
a reliable method to determine the copy number of transgenic mice (Pfeifer et al, 2010). 
Hence, ES cell populations by transducing ES cells with different LV concentrations were 
generated and analyzed using qPCR (Figure 38A). These LV-transduced ES cell 
populations without additional selections are further referred to as mixed ES cell 
populations. qPCR data were validated by comparison with samples of known number of 
integrants (one and two LV-integrants) that have been proven by Southern Blot analysis 
(Figure 38B). ES cell populations with an average copy number of 1.5 provirus 
integrations per genome were chosen for further analysis (1.60±0.09 (NT) and 1.38±0.24 
(OT) (Mean±SEM)) (Figure 38C). 
 
Figure 38: Copy number analysis of NT- or OT-transduced ES cells (mixed population). (A) Schematic 
illustration of qPCR-primers and probes for detection of house-keeping gene Burkitt lymphoma receptor 1 
(BLR1) and long terminal repeat (LTR) of integrated LVs for determination of number of provirus 
integrations in ES cells. Copy number of LV per genome is determined by the means of the cycle threshold 
(Ct) values by using following formulas: copy number=2
ΔCt with ΔCt=Ct(BLR1)-Ct(Late-RT). (B) Southern 
blot analysis of LV-mediated transgenic mice carrying one or two integrants. The gDNA of these two mice 
were used as control in qPCR analysis. (C) ES cells were not transduced (WT) or transduced with different 
amount of NT or OT. Mixed ES cell populations were tested using qPCR. Shown are the results of mixed ES 
cell populations carrying 1.5 provirus integrants per genome in average (n=3, Mean±SEM, N.S., not 
significant difference, ANOVA, analysis of variance).  
GCV treatment of these undifferentiated mixed ES cell populations strongly inhibited cell 
survival as shown on bright field images (Figure 39A). 
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Figure 39: Analysis of NT- or OT-transduced ES cells (mixed population) with an average copy 
number of 1.5 per genome. (A) Brightfield images of mixed ES cell populations without (WT) or with (NT, 
OT) LV transduction with (+) or without (-) 20µM GCV treatment under undifferentiation conditions. 
Representative brightfield images are shown (n=3). (B) Brightfield and fluorescence images of EBs derived 
from untransduced (WT) and NT- or OT-transduced ES cells (mixed populations) carrying 1.5 copy numbers 
per genome in average on day 14 post differentiation with (+) or without (-) 20µM GCV. eGFP expression 
driven by cardiac specific promoter α-MHC indicates formation of ES cell-derived cardiomyocytes. 
Fluorescence images of dissociated EBs after differentiation demonstrated that 
untransduced and NT- or OT-transduced EBs (with or without GCV) expressed eGFP, 
indicating a normal formation of ES cell-derived cardiomyocytes and no influence of GCV 
treatment (Figure 39B). 
Next, immunostaining of differentiated cells was performed using antibody against Oct-3/4 
and Hoechst (Figure 40A). 
 
Figure 40: Analysis of dissociated EBs derived from untransduced (WT) and NT- or OT-transduced 
ES cells with 1.5 copy numbers per genome in average using immunochemistry. (A) Untransduced (WT) 
or NT- or OT-transduced ES cells were differentiated (+/- 20 µM GCV)  and immunostaining of dissociated 
EBs on day 14 with Oct-3/4 (red) and Hoechst (blue) was performed indicating undifferentiated ES cells and 
nucleus, respectively. Representative fluorescence images are shown (n=3). (B) Percentage of Oct-3/4-
positive cells of dissociated EBs on day 14 post differentiation with (+) and without (-) GCV treatment as 
analyzed by cell counting of images representatively shown in (A) (n=5, Mean±SEM, **P<0.001, ANOVA, 
analysis of variance). 
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Images were taken using fluorescence microscopy (Figure 40A) and Oct-3/4-positive cells 
were counted (Figure 40B). Importantly, GCV treatment of differentiated NT- or OT-
transduced ES cells significantly reduced the survival of Oct-3/4-positive cells as 
compared to untransduced cells (3.58%±1.58 (NT) and 2.97%±0.88 (OT) vs. 13.12%±2.20 
(WT)) (Figure 40B). 
Next, dissociated EBs were again analyzed by using immunostaining against α-actinin and 
by fluorescence detection of cardiac specific promoter driven eGFP expression (Figure 41). 
Again, formations of ES cell-derived cardiomyocytes suggested that the TK/GCV system 
allows normal ES cell differentiation of NT- or OT-transduced ES cells carrying 1.5 copy 
numbers in average per genome and has no influence on the cell development. 
 
Figure 41: Immunostaining of dissociated EBs derived from untransduced (WT) and NT- or OT-
transduced ES cells with 1.5 copy numbers per genome in average. Dissociated EBs were stained with 
antibody against skeletal α-actinin (sarcomere) indicating the successful formation of ES cell-derived 
cardiomyocytes (white); green fluorescence indicates eGFP expression driven by cardiac specific promoter, 
α-MHC. 
Taken together, LV-transduced mixed ES cell populations with low copy numbers revealed 
a significant killing efficiency upon GCV treatment. Nevertheless, the mixed populations 
still contained around 3 to 4% Oct-3/4-positive cells on day 14 post differentiation (see 
also Figure 40B) suggesting a potential risk of teratoma formation in vivo (Gropp et al, 
2012). This presence of Oct-3/4-positive cells could result from an insufficient TK 
expression level of OT- or NT-transduced ES cells or due to remaining untransduced ES 
cells. Thus, both approaches were investigated in detail to improve the efficiency to 
eliminate undifferentiated cells.  
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3.2.3.2. Use of EOS promoters to drive TK expression 
In order to achieve higher levels of TK expression, the promoter of pluripotency genes 
EOS-C3 and EOS-S4 were applied that have been shown be stronger than Nanog or Oct in 
human and murine ES and iPS cells (Hotta et al, 2009). These two promoters were cloned 
into the LV backbone leading to LV-constructs EOS-C3-TK (CT) and EOS-S4-TK (ST) 
(Figure 42A). The four LVs (NT, OT, CT, ST) were then used in parallel for transduction 
of ES cells and LV integrations were each determined using qPCR. ES cell populations 
with an average copy number of approximately 1.5 per genome were further investigated 
(Figure 42B).  
 
Figure 42: Use of different promoters of pluripotency genes EOS-C3 and EOS-S4 in LVs to drive TK 
expression. (A) Constructs of LVs carrying TK cDNA driven by promoters EOS-C3 or EOS-S4 led to LVs 
EOS-C3-TK (CT) or EOS-S4-TK (ST). (B) Copy number of NT-, OT-, CT- and ST-transduced ES cells as 
analyzed by qPCR (n=3, Mean±SEM, N.S., not significant, ANOVA, analysis of variance). As control, DNA 
of two transgenic mice was used that were previously analyzed by Southern Blot to have one or two LV 
integrants. 
 
Next, the mixed ES cell populations carrying 1.5 copy numbers per genome in average 
were analyzed concerning their TK expression on mRNA level (Figure 43A) and protein 
level (Figure 43B) that was detected using qPCR and Western Blot analysis, respectively. 
These experiments revealed that both promoters of pluripotency genes, EOS-C3 and EOS-
S4, gave rise to more mRNA and subsequently even more TK protein compared to Nanog 
and Oct promoters in murine ES cells (Figure 43A, B). Using EOS-S4 promoter to drive 
TK expression, the highest TK abundance was obtained (Figure 43A, B).  
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Figure 43: Analysis of TK expression of NT-, OT-, CT- and ST-transduced ES cells carrying 1.5 copy 
numbers per genome in average. (A) TK expression on mRNA level of NT-, OT-, CT- and ST-transduced 
ES cells as analyzed by qPCR and normalized to GAPDH (n=3, Mean±SEM, *P<0.05, **P<0, ANOVA). (B) 
Western Blot of NT-, OT-, CT- and ST-transduced ES cells with antibody against TK. As loading control 
Tubulin was used. 
The four mixed ES cell populations were then analyzed concerning the efficiency of the 
TK/GCV system under undifferentiation conditions. Brightfield images (Figure 44A) 
showed no obvious difference in the killing efficiency. In addition, a Lactate 
Dehydrogenase (LDH) assay was applied. 
 
Figure 44: Analysis of ES cells transduced with LVs using different promoters of pluripotency genes. 
(A) Brightfield images of NT-, OT-, CT- and ST-transduced (1.5 copies per genome in average) and not 
transduced (WT) ES cells after 72 hours treatment with 20µM GCV under undifferentiation conditions are 
shown. (Representative images of n=3). (B) NT, OT, CT, ST transduced (1.5 copies per genome in average) 
or not transduced (WT) ES cells were treated for 72 hours with (+) or without (-) 20µM GCV. Cell culture 
supernatants were either directly analyzed using LDH assay or LDH was measured after complete lysis of 
cells of each set of samples. The differences of extinction with and without lysis were determined 
representing the number of ES cells that survived GCV treatment. Feeder cell derived LDH release was each 
substracted. Relative survivals of GCV treated NT, OT, ST and CT cells as compared to WT are shown. (n=3, 
Mean±SEM, ***P<0.001, compared to WT, N.S., not significant, ANOVA, analysis of variance). 
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The assay measures LDH that is released by dead cells into the cell culture supernatant. 
Interestingly, a higher TK expression level did only slightly increase the effect of GCV on 
ES cells (Figure 44B) demonstrating that the portion of surviving cells is rather the 
consequence of incomplete transduction of the ES cell population than of low TK 
expression. 
 
3.2.3.3. LVs-mediated TK expression in single copy ES cell clones  
The application of the TK/GCV system in mixed ES cell populations with 1.5 copy 
numbers per genome in average resulted in a survival of around 3-4% Oct-3/4-positive 
cells after GCV treatment of NT- or OT-transduced cells (see also Figure 40B). 
Furthermore, an increase of TK expression (as shown on mRNA or protein level) had no 
additional effect on the survival of undifferentiated cells after GCV treatment (Figure 44B). 
However, a complete elimination of undifferentiated cells should be reached, since already 
a few pluripotent cells could lead to formation of teratomas (Gropp et al, 2012). 
Transducing ES cells with LVs carrying the TK cassette without further selection (mixed 
ES cell populations) would always leave a certain percentage of cells remaining 
untransduced. These cells will not be eliminated by GCV treatment. Therefore, NT or OT 
expressing ES cell lines derived from picked clones were generated and ES cell clones 
carrying only one integrant per genome were chosen for further analysis to improve the 
efficiency of the TK/GCV system. LV integrations of those ES cell lines were proven by 
Southern blot analysis and two different single-integrant clones of both NT- or OT-
transduced ES cells were used for further investigations (NT #8, NT #11, OT #4, OT #11) 
(Figure 45A, B). 
 
Figure 45: Southern blot analysis of NT- or OT-transduced ES cell clones. ES cells were transduced with 
NT (A) or OT (B) and picked clones were analyzed by Southern Blot. Marked are the results of the single LV 
integrant ES cell clones. NT transduced ES cell clones are highlighted by white arrows. Unspecific bands are 
indicated by asterisk (*). (A) Single copy NT-transduced ES cell clones: NT #8 and NT #11 (white arrows). 
(B) Single copy OT-transduced ES cell clones: OT #4 and OT #11. 
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Next, the four ES cell clones were cultured under undifferentiation and differentiation 
conditions with or without GCV treatment. This showed that the cells of all four clones 
were completely eliminated upon GCV treatment under undifferentiation conditions 
(Figure 46A). Under differentiation conditions, untransduced and NT- or OT-transduced 
EBs expressed eGFP indicating the successful formation of ES cell-derived 
cardiomyocytes (Figure 46B). 
 
Figure 46: Analysis of single copy NT- or OT-transduced ES cell clones in vitro. (A) ES cells were 
transduced with NT or OT or not transduced (WT) and single ES cell clones carrying each one integrant were 
further cultured upon treatment with (+) or without (-) 20 µM GCV. Representative brightfield images of n=3 
are shown. (B) ES cell lines from (A) were cultured under differentiation conditions for 14 days. Brightfield 
and fluorescence images of EBs derived from untransduced (WT) and NT or OT single copy ES cell clones 
(NT #8, NT #11, OT#4 and OT #11) on day 14 post differentiation are shown. eGFP expression driven by 
cardiac specific promoter α-MHC indicates formation of ES cell-derived cardiomyocytes. 
 
The EBs derived from cultivation under differentiation condition were further dissociated 
and immunostained using antibodies againstOct-3/4 and Hoechst (Figure 47A).  
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Figure 47: Analysis of dissociated EBs derived from untransduced (WT) and single copy NT- or OT-
transduced ES cell clones using immunostaining. (A) Untransduced or single copy NT or OT ES cell 
clones (+/- 20 µM GCV) were differentiated and immunostaining of dissociated EBs on day 14 with Oct-3/4 
(red) and Hoechst (blue) was performed indicating undifferentiated ES cells and nucleus, respectively. 
Representative images are shown (n=3). (B) Percentage of Oct-3/4-positive cells of dissociated EBs on day 
14 post differentiation with (+) and without (-) GCV treatment as analyzed by cell counting of images 
representatively shown in (A) (n=3, Mean±SEM, ***P<0.001, ANOVA, analysis of variance). 
Importantly, the four ES cell clones revealed only 1.51%±0.72 (NT #8), 1.51%±0.64 (NT 
#11), 0.45%±0.16 (OT #4) and 0.26%±0.26 (OT #11) (Mean±SEM) surviving Oct-3/4-
positive cells present on day 14 post differentiation when treated with GCV (Figure 47B). 
Again, the differentiation of the ES cells of all four clones into ES cell-derived 
cardiomyocytes was not influenced by the LV transduction or the GCV treatment as shown 
by immunostaining against skeletal α-actinin and fluorescence detection of cardiac specific 
promoter driven eGFP expression (Figure 48). 
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Figure 48: Immunostaining of dissociated EBs derived from untransduced (WT) or single copy NT- or 
OT-transduced ES cell clones. Dissociated EBs on day 14 post differentiation were stained with antibody 
against skeletal α-actinin (sarcomere) indicating the successful formation of ES cell-derived cardiomyocytes 
(white); green fluorescence indicates eGFP expression driven by cardiac specific promoter, α-MHC. 
 
3.2.3.4. LV-mediated TK expression in mixed ES cell population using Hygromycin pre-
selection 
As compared to mixed ES cell populations (see also Figure 40B), the use of single 
integrant NT- and OT-transduced ES cell clones led to a more efficient elimination of 
undifferentiated cells after GCV treatment (see also figure 47B). However, these two 
approaches can not abolish undifferentiated cells completely and are not efficient enough 
for future clinical applications. Importantly, all ES cells for clinical use should be 
transduced by LVs containing TK cDNA to enable a complete elimination of 
undifferentiated cells upon GCV treatment. Therefore, for excluding the untransduced ES 
cells from mixed populations an antibiotic pre-selection scheme was chosen: A 
hygromycin resistance gene expression cassette was incorporated in the ST construct 
leading to construct EOS-S4-TK-PGK-Hygromycin (STPH) (Figure 49). The hygromycin 
resistance gene was under the control of the ubiquitous PGK promoter enabling 
hygromycin selection of successfully transduced ES cells of each state. For incorporating 
the selection cassette the construct ST was chosen, as this LV resulted in the highest TK 
abundance although no higher efficiency of TK/GCV system was obtained (see also 
Figures 43 and 44). 
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Figure 49: Construct of LV double cassette containing a hygromycin resistance gene driven by PGK 
promoter and TK cDNA under the control of EOS-S4 promoter (STPH). 
The STPH construct was then used for transduction of ES cells and mixed ES cell 
populations with an average copy number per genome of 1.5 were further investigated 
(data not shown). The cells were treated with GCV with or without hygromycin pre-
selection under undifferentiation conditions (Figure 50). 
 
Figure 50: Analysis of ES cells transduced with STPH with 1.5 copy numbers per genome in average 
under undifferentiation conditions. (A) Brightfield images of untransduced (WT) or STPH-transduced ES 
cells with (+Hygro) or without hygromycin (-Hygro) pre-selection and with (+) or without (-) 20 µM GCV 
treatment under undifferentiation conditions. Representative brightfield images are shown (n=3). (B), (C) and 
(D) Relative cell survival of untransduced ES cells (WT) (B), STPH-transduced ES cells without pre-
selection (C) and STPH-transduced ES cells with pre-selection (D) with (+) or without (-) 20 µM GCV 
treatment as analyzed by cell counting of images representatively shown in (A) (n=3, Mean±SEM, 
***P<0.001 compared to without GCV treatment, respectively, t-test). 
In addition to taking brightfield images (Figure 50A) ES cells were also counted (Figures 
50 B to D). The GCV treatment of the unselected STPH-transduced ES cells resulted in a 
significant reduction of undifferentiated cells (47.30%±0.37, Mean±SEM) as compared to 
unselected STPH transduced cells without GCV application (Figure 50A, C). 
Untransduced cells showed no difference with or without GCV (Figure 50A, B). 
Importantly, with hygromycin pre-selection, only 0.37%±0.29 undifferentiated STPH-
transduced ES cells were observed in the presence of GCV indicating that pre-selection is 
necessary for complete abolishment of ES cells in vitro (Figure 50A, D). 
In the following, the STPH-transduced ES cells with low copy numbers were differentiated 
into EBs. Fluorescence analysis of α-MHC driven eGFP expression in the EBs showed the 
eGFP expression in all cell populations indicating successful formation of ES cell-derived 
cardiomyocytes (Figure 51A). Immunostaining of Oct-3/4-positive cells on day 14 post 
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differentiation revealed no Oct-3/4-positive cells after GCV treatment of pre-selected cells 
indicating successful elimination of undifferentiated cells (Figure 51B).  
 
Figure 51: Differentiation of STPH-transduced ES cells. (A) Brightfield and fluorescence images of EBs 
derived from untransduced (WT) or STPH-transduced mixed ES cell populations carrying 1.5 copy number 
per genome in average on day 14 post differentiation and treated with (+) or without (-) 20 µM GCV after 
pre-selection with (+Hygro) or without hygromycin (-Hygro). Representative images are shown (n=3). eGFP 
expression driven by cardiac specific promoter α-MHC imdicates formation of ES cell-derived 
cardiomyocytes. (B) Immunostaining of dissociated EBs form (A) with Oct-3/4 (red) and Hoechst (blue) 
indicating Oct-3/4-positive cells (ES cells) and nucleus, respectively. Representative images are shown (n=3). 
 
Again, formation of ES cell-derived cardiomyocytes from these STPH-transduced ES cells 
was analyzed and revealed again no influence of TK/GCV on the differentiation process as 
shown by immunostaining against skeletal α-actinin and fluorescence detection of cardiac 
specific promoter driven eGFP expression (Figure 52). 
 
Figure 52: Immunostaining of dissociated EBs of STPH-transduced ES cells. Dissociated EBs from 
untransduced (WT) or STPH-transduced mixed ES cells populations with (+) or without (-) 20 µM GCV 
treatment after pre-selection with (+Hygro) or without hygromycin (-Hygro) were immunostained with 
skeletal α-actinin (sarcomere) indicating the successful formation of ES cell-derived cardiomyocytes (white); 
green fluorescence indicates eGFP expression driven by cardiac specific promoter, α-MHC.  
 
Results 
89 
 
However, for a more convenient use of ES cells in clinical applications renouncement of 
additional pre-selection would be worthwhile. Therefore, higher lentiviral copy numbers in 
ES cells without pre-selection might result in a similar efficiency. Thus, ES cells were 
transduced with higher LV concentrations of STPH leading to an average copy number of 
3.8 as analyzed by qPCR (data not shown). GCV treatment of these cells carrying high 
copy numbers without pre-selection showed in vitro a strong elimination of 
undifferentiated cells (35.43%±2.00, Mean±SEM) as shown by brightfield images (Figure 
53A) and cell counting (Figure 53B, C). 
 
Figure 53: Analysis of STPH-transduced ES cells with high copy number. (A) ES cells were not 
transduced (WT) or were transduced with different concentrations of LV STPH leading to 3.8 copy number 
(high copy number) per genome in average and treated with (+) or without (-) 20 µM GCV without (-) 
Hygromycin. Representative brightfield images are shown (n=3). (B) and (C) Relative cell survival of 
untransduced ES cells (WT) (B) or STPH-transduced ES cells (C) with (+) or without (-) 20 µM GCV 
treatment as analyzed by cell counting of images representatively shown in (A) (n=3, Mean±SEM; 
***P<0.001 compared to without GCV treatment, respectively, Student’s t-test). 
These data demonstrate that increasing the copy number significantly increases the 
elimination efficiency of TK/GCV system as compared to low copy number STPH 
transduced ES cells (see also Figure 50C). Unfortunately, complete killing of 
undifferentiated cells was not achieved as observed for pre-selected low copy number 
STPH transduced ES cells (see also Figure 50D). 
Taken together, hygromycin application on STPH-transduced ES cells of low copy number 
resulted in successful selection of only transduced ES cells and thus, an extremely efficient 
elimination of undifferentiated cells was achieved upon GCV treatment. However, 
increasing the lentiviral copy number showed lower cell survival of undifferentiated cells 
without pre-selection. But the complete elimination of ES cells was not achieved and thus, 
pre-selection seems to be necessary. 
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3.2.4. in vivo application of TK expressing ES cells  
3.2.4.1. in vivo application of STPH-transduced ES cells with low copy numbers  
Since in vitro data revealed an efficient elimination of undifferentiated ES cells after STPH 
transduction, hygromycin pre-selection and GCV treatment, the system was also tested in 
vivo. Therefore, 1x10
6
 untransduced or STPH-transduced ES cells with hygromycin pre-
selection were injected into the left and right hind limbs of 8-week old SCID®  mice, 
respectively (Figure 54). Three hours after ES cell injection, the mice were administered 
with either saline solution (0.9% (w/v) NaCl) or with 20 mg/kg GCV per day for 12 days. 
 
Figure 54: Schematic illustration of in vivo application of ES cells. 1x10
6
 ES cells (untransduced (WT) or 
STPH transduced) were injected into hind limbs of SCID mice. Saline solution or GCV (20mg/kg/day) were 
administrated by intraperitoneal injections (i.p.) for 12 days. 
Three weeks after ES cells injection the mice were sacrificed for analysis of potential 
teratoma formation. Teratomas were weighed, measured concerning their dimensions and 
used for H&E staining. No significant difference in the weights of teratomas was detected 
in mice treated with saline solution after injection of both untransduced and pre-selected 
STPH-transduced ES cells (Figure 55A, B). Importantly, applying STPH-transduced ES 
cells with pre-selection and subsequent GCV administration resulted in only one out of six 
mice that revealed the formation of only a small tissue (Figure 55B, C and Table 3). This 
clearly indicates the prevention of teratoma formation. 
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Figure 55: in vivo application of STPH-transduced ES cells (low copy) with hygromycin pre-selection. 
Three weeks after injections of 1x10
6
 ES cells (STPH-transduced with 1.5 copies per genome in average or 
not transduced (WT)) into hind limbs of SCID/beige mice and administration with Saline solution (0.9% (w/v) 
NaCl) or GCV (20mg/kg/day) for 12 days, the mice were sacrificed for analysis of teratoma formation. (A) 
and (B) Images of ES cell injected mice and dissected teratomas. (C) Relative weight of teratoma from 
engraftment of WT and hygromycin pre-selected STPH-transduced ES cells with low copy number (L (1.5 
copies per genome in average)) with (+) or without (-) GCV treatment (n=4 or 6, Mean±SEM; ***P<0.001, 
ANOVA, analysis of variance). 
Teratomas derived from injection of STPH-transduced ES cells with both saline and GCV 
treatment were further investigated by applying H&E staining (2.13). Expectedly, stained 
teratoma sections exhibited tissues from all of the three germ layers in case of saline 
treatment (Figure 56A). In contrast, the small tissue obtained from one out of six mice that 
all received STPH transduced pre-selected ES cells and GCV treatment showed only 
muscle tissue without any other germ layer tissue (Figure 56 B). 
 
Figure 56: H&E staining of teratomas derived from in vivo application of STPH-transduced ES cells 
with hygromycin pre-selection. (A) and (B) H&E stained sections of explanted teratomas emerging from 
injections of pre-selected STPH-transduced ES cells without GCV (A) or with GCV treatment (B) 
demonstrating muscle (left), cartilage, glandular epithelium and neural tissue (right) as indicated. 
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In addition, the average size of teratomas (maximal dimensions) was measured (Table 3). 
If untransduced (WT) cells were injected, teratoma dimensions of more than 1cm were 
observed for both saline and GCV treatment indicating no influence of GCV alone (Table 
3). Similar teratoma dimensions were detected after injection of STPH-transduced ES cells 
(low copy numbers) with pre-selection in absence of GCV (Table 3). In contrast, injection 
of STPH-transduced ES cells with pre-selection upon GCV application exhibited only 
muscle tissue (see also Figure 56B) with a diameter of only ~0.3 cm (Table 3). No 
teratoma or tissue was detected in all other mice of this group (Table 3).  
Table 3: Summary of teratoma dimensions formed from ES cells injected in hind limbs of SCID/beige 
mice 
The table summarizes the ES cell injections into hind limbs of SCID/beige mice and teratomas were analyzed 3 weeks 
later. Teratoma size (>1 cm or <1 cm) indicates maximum dimension. 
aES cells were transduced with STPH (+STPH) or not transduced (w/o virus), respectively. 
H and L indicate ES cells carrying high (3.8) or low (1.5) copy number per genome in average. 
bHygromycin pre-selected ES cells were cultured with 300ng/ml hygromycin for 9 days before ES cell injection. 
cES cells were injected and mice were treated with (+) or without (-) 20mg/kg/day GCV for 12 days. GCV-untreated 
mice received the same volume of 0.9% (w/v) NaCl. 
dTeratoma’s diameter is less than 0.3 cm and exhibit only muscle tissue (see also Figure 56B). 
 
In conclusion, ES cells that have teratoma-forming potential seemed to be completely 
eliminated due to GCV application in vivo if a pre-selection of LV-transduced ES cells is 
performed. These results confirmed the in vitro findings (see also Figure 50D). . 
Importantly, these results were obtained with cells carrying only 1.5 provirus integrations 
per genome in average. Mixed ES cell populations were applied for hygromycin treatment 
without the need of further clone picking or additional screening, e.g. by southern blot 
analysis. This suggests promising future for use in regenerative medicine approaches 
 
Cell line
a
 Hygromycin 
selection
b
 
GCV 
Treatment
c
 
n Teratoma 
> 1 cm 
Teratoma 
< 1 cm 
No 
teratoma 
ES w/o virus - - 9 8/9 1/9 - 
ES w/o virus - + 11 11/11 - - 
ES + STPH (H) - - 5 5/5 - - 
ES + STPH (H) - + 5 1/5 4/5 - 
ES + STPH (L) + - 4 4/4 - - 
ES + STPH (L) + + 6 - 1
 d
 /6 5/6 
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3.2.4.2. in vivo application of STPH-transduced ES cells with high copy numbers 
In addition, STPH-transduced ES cells carrying high copy numbers without pre-selection 
were also investigated in vivo. When treating the mice with saline, similar teratoma 
weights were observed for both injections of untransduced and of STPH-transduced cells 
without pre-selection (Figure 57A, C).  
 
Figure 57: in vivo application of STPH-transduced ES cells (high copy) without hygromycin pre-
selection. Three weeks after injections of 1x10
6
 ES cells (STPH-transduced with 3.8 copies per genome in 
average or not transduced (WT)) into hind limbs of SCID/beige mice and administration with Saline solution 
(0.9% (w/v) NaCl) or GCV (20mg/kg/day) for 12 days, the mice were sacrificed for analysis of teratoma 
formation. (A) and (B) Images of ES cell injected mice and dissected teratomas. (C) Relative weight of 
teratoma from engraftment of WT and non-selected (-Hygro) STPH-transduced ES cells with high copy 
number (H (3.8 copies per genome in average)) with (+) or without (-) GCV treatment (n=5, Mean±SEM; 
***P<0.001, ANOVA, analysis of variance).  
All of these mice developed teratomas with maximum dimensions of more than 1 cm 
(Table 3). Compared to the control group that received untransduced cells, a significant 
reduction in teratoma weight (around 65%) was observed for injection of high copy 
number STPH-transduced ES cells without pre-selection when GCV was applied (Figure 
57B, C). Furthermore, four out of five mice showed formation of only small teratomas 
upon GCV treatment (Table 3). However, higher LV copy number of STPH-transduced ES 
cells without pre-selection could not result in a complete absence of teratomas as observed 
for injection of pre-selected low copy number STPH-transduced ES cells (see also Figure 
55B, C). 
These in vivo results confirmed the in vitro findings (see also Figure 53C) where also no 
complete elimination of undifferentiated ES cells was achieved that have teratoma-forming 
potential. It was figured out, that pre-selection of LV-transduced ES cells is much more 
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favorable than increasing LV doses. Although, the hygromycin pre-selection represents an 
additional step in cell preparing before injection, it is an easy-to-handle method. 
Importantly, the risk of insertional mutagenesis due to integrating LVs can be reduced as 
only low copy numbers are sufficient to avoid tumor formation.  
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4. Discussion 
Within the first part of the work epigenetic regulation of the transgene cassette in ES cells 
was analyzed after viral transduction with either LVs or RVs. Both viral vectors belong to 
the family of Retroviridae and are either based on HIV-1 or on MLV.  
4.1. RVs and LVs transgenesis and gene therapy 
In the early 1950’s it has been discovered that mouse leukemia is transmitted to newborn 
mice by an agent that is still acting after filtration (Gross, 1951a; Gross, 1951b). It turned 
out that the causer was a virus. Starting from these studies deeper insights in the life cycle 
of retroviruses have been revealed and retroviral vector system have been developed.  RVs 
have even been used as vehicles in the context of gene therapy (Rein, 2011) as they are 
able to stably integrate into the genome of target cells, which leads to persistent expression 
of the transgene (Pfeifer & Verma, 2001a). In contrast to a simple retroviruses such as 
MLV, a complex retrovirus like the lentivirus  human immunodeficiency virus HIV-1 
contains additional regulatory and accessory genes (Coffin, 1992; Vogt, 1997). These two 
viruses differ also in their infectivity: HIV-1 can efficiently infect nondividing cells 
(Naldini et al, 1996) whereas MLV generally does not (Lewis & Emerman, 1994; 
Yamashita & Emerman, 2006). This distinctive feature provides broad spectrum toward 
many applications of lentivirus-derived vectors for which MLV are not favorable. 
However, it has been reported that very few nondividing cells including human 
macrophages or post-mitotic neural cells could be transduced with simple retrovirus-
derived vectors (Jarrosson-Wuilleme et al, 2006; Liu et al, 2011).  
The integration site of HIV-1 and MLV is not purely random, but both viruses have 
different preferences (Bushman, 2002; Schroder et al, 2002; Wu et al, 2003). The 
integration site of HIV-1 is influenced by a verity of factors including specific cellular 
protein binding to viral integrase (Lewinski et al, 2006). HIV-1 prefers to integrate in 
transcriptionally active regions of the host genome (Mitchell et al, 2004; Schroder et al, 
2002). For MLVs, cellular factors including higher order chromatin structures are likely to 
affect accessibility to target DNA (Rohdewohld et al, 1987; Vijaya et al, 1986). In detail, 
MLV particularly favors transcriptional start sites, regions near DNase I hypersensitivity 
sites (Rohdewohld et al, 1987; Vijaya et al, 1986) as well as CpG islands (Qasim et al, 
2010; Wu et al, 2003). Around 17% of MLV integrate within human CpG islands (± 1 kb) 
whereas only 2% of HIVs integrate within these sites (Wu et al, 2003). 
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 Compared to RVs, LVs can accommodate larger transgene expression cassettes (up to ~ 8 
kb) (De Meyer et al, 2006; Zufferey et al, 1998). In addition, compared to other gene 
transfer vehicles like adenovirus or adeno-associated virus vectors (Chirmule et al, 1999; 
Mingozzi et al, 2007), LVs showed a decreased immunogenicity in in vivo applications 
(Abordo-Adesida et al, 2005). So far, LVs have been already proved to be safe in ex vivo 
gene therapy in the context of human clinical trials (Cartier et al, 2009; Cavazzana-Calvo 
et al, 2010; Huang et al, 2006).  
RVs have been also applied for different clinical approaches. However, a serious drawback 
related to the risk of retrovirus-mediated insertional mutagenesis leading to aberrant gene 
expressions was observed in a clinical trial for X-linked severe combined 
immunodeficiency disease (SCID) (Hacein-Bey-Abina et al, 2003). It has recently been 
shown that autologous stem cell gene therapy by using RVs for X-linked SCID treatment 
also caused T cell leukemiagenesis (Hacein-Bey-Abina et al, 2008; Howe et al, 2008). 
Furthermore, transactivation of retroviral insertion led to clonal expansion of myeloid cells 
when RVs were used for genetic modification of hematopoietic stem cells (HSCs) (Ott et 
al, 2006). In contrast, there are two early reports showing no insertional mutagenesis in 
patients that were treated with autologous T cells modified ex vivo by using LVs 
transduction (Levine et al, 2006; Wang et al, 2009). 
Prototypic 3’ LTR enhancer/promoter elements of integrated wildtype RVs or wildtype 
LVs in host genome could cause the aberrant activation of downstream flanking genes. 
Therefore, the wildtype 3’ LTR enhancer/promoter elements by applying self-inactivation 
(SIN) of the viral vectors (refer to 1.4 for detailed information) leading to SIN-LVs 
(Zufferey et al, 1998) as well as SIN-RVs (Yu et al, 1986). Importantly, SIN-LVs and SIN-
RVs lacking of wildtype 3’ LTR enhancers/promoters were considered to be safe to be 
used as gene transfer vehicles (Lever et al, 2004; Yu et al, 1986). Nevertheless, strong 
residual promoter activity was still observed in the 3′ LTR of many currently used SIN-
RVs, which may raise the potential risk of insertional mutagenesis (Xu et al, 2012). 
However, this same phenomenon was so far not found in SIN-LVs (Xu et al, 2012; 
Zufferey et al, 1998). Some other reports also suggested that SIN-LVs transduction are 
more favorable compared to applying retroviral  MLV backbone with the same SIN 
configuration due to the higher risk of insertional mutagenesis of SIN-RVs (Modlich et al, 
2009; Qasim et al, 2010).  
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4.2. Epigenetic regulation of SIN-RVs and SIN-LVs in vitro  
As there are some differences between SIN-LVs and SIN-RVs the goal of the first part of 
the present work was the investigation of epigenetic regulation of SIN-LVs and SIN-RVs 
in transduced ES cells. Early studies demonstrated that de nova methylation of CpG 
nucleotides appeared to be a major reason for the transcriptional inactivation of retrovirus 
during mouse embryogenesis (Challita & Kohn, 1994; Cherry et al, 2000; Jahner et al, 
1982; Laker et al, 1998). However, de nova methylase independent silencing of LVs in ES 
cells had also been reported (Pannell et al, 2000). In addition, hypoacetylation of histone 
H3 and H1 in ES cells played an important role in transgene silencing (Yao et al, 2004). To 
minimize transgene silencing of viral vectors due to methylation of provirus in host cells, 
SIN vectors have been developed lacking a number of viral elements that are potential 
targets for the host cellular silencing machinery (Yu et al, 1986; Zufferey et al, 1998). 
Indeed, most wildtype viral vectors were silenced in host cells, but in case of SIN vectors 
only half of the integration sites were silenced (Osborne et al, 1999; Pannell et al, 2000). A 
study comparing the activity of SIN-LVs and wildtype RVs in murine ES cells showed that 
transgene expression in SIN-LV-transduced ES cells was still observed during cell 
differentiation (Hamaguchi et al, 2000). In contrast, the transgene expression dramatically 
declined in RVs-transduced ES cells (Hamaguchi et al, 2000). Although, methylation and 
histone modification of SIN-LVs were still found in murine embryonic carcinoma cells, 
SIN-LVs generally displayed a significantly better performance as compared to the 
prototypic retroviruses (He et al, 2005). 
However, Schambach et al have reported that SIN-RVs showed the similar properties as 
SIN-LVs in hematopoietic stem cells (Schambach et al, 2006a) when using identical 
enhancer, promoter and transgene cassette sequences. In that study they did not investigate 
the fate of SIN-RVs in ES cells under differentiation conditions or in in vivo experiments. 
Therefore, in the present study, SIN-LVs and SIN-RVs were applied in ES cells under 
undifferentiation as well as differentiation conditions. Under undifferentiation conditions, 
these two vectors exhibited the same stable expression of transgene in mixed ES cell 
populations (i. e. without further selection) as already reported by Schambach et al. 
Surprisingly, under differentiation conditions, the transgene expression in both cases 
declined at day 5 post differentiation (see also Figure 13) due to provirus methylation (see 
also Figure 16 and 17). 
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For further analysis of SIN-LV- and SIN-RV-mediated gene expression, single copy clones 
of transduced ES cells were picked and SIN-LV and SIN-RV ES cell clones with “high 
expression level” or with “low expression level” were investigated, respectively. These 
single clones all showed a stable transgene expression under undifferentiation conditions 
as already observed for mixed ES cell populations. Nevertheless, only the high expressing 
SIN-LV ES cell clone maintained transgene expression when cells underwent 
differentiation, whereas the low expressing SIN-LV clone and both low or high expressing 
SIN-RV clones did not. The analysis of methylation status was performed using 
methylation-sensitive Southern Blot as well as the high-resolution method of sodium 
bisulfite sequencing. These data revealed that a much higher level of methylation occur in 
the low expressing SIN-LV clone and the low and high expressing SIN-RV clones as 
compared to the high expressing SIN-LV clone. This indicates that provirus methylation is 
one of the main reasons for the transgene silencing. A former study has proposed that 
application of the methyltransferase inhibitor 5’-Aza in differentiated ES cells could 
partially reactivate the silenced transgene if silencing is due to cytosine methylation (Yao 
et al, 2004). However, application of 5’-Aza in differentiated ES cell clones did not reverse 
transgene silencing in the present study (see also Figure 22C). Moreover, high 
concentrations of 5’-Aza showed cellular toxicity in ES cells. 
The main reason for transgene silencing in the four clones under differentiation conditions 
seems to be the de novo methylation of CpG nucleotides. However, the role of histone 
acetylation could not be excluded. This could be further investigated by either applying the 
histone deacetylase inhibitors Trichostatin A (TSA) on silenced ES cell clones (Yao et al, 
2004) or by use of the de novo methylase-null [dnmt3a-/-; dnmt3b-/-] ES cell line (Pannell 
et al, 2000). Transgene silencing resulting from histone modification in single copy SIN-
LVs or SIN-RVs ES cell clones were not investigated in the scope of the present work and 
require further investigation. 
 
4.3. Epigenetic regulation of SIN-RVs and SIN-LVs in vivo 
To investigate the fate of viral vectors in vivo generation of transgenic animals is a suitable 
method. It enables steady monitoring of the activity of viral vectors during embryogenesis 
and of the transgene expression in the transgenic livestock. Previous studies showed that 
lentiviral vectors are able to efficiently transduce human ES cells and pre-implantation 
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embryos of mice and rats (Lois et al, 2002; Pfeifer et al, 2002). Additionally, farm 
transgenic livestock were also successfully generated by applying subzonal injections of 
LVs, i.e. transgenic pigs (Hofmann et al, 2003) or cattles (Hofmann et al, 2004). By now 
SIN-LVs are well accepted as efficient vehicles for gene delivery in vitro as well as in vivo. 
Their potential for the generation of transgenic animals has been recognized as a promising 
alternative to the conventional DNA-microinjection method (Chan et al, 1998; Wells et al, 
1999). In contrast, using wildtype RVs as vehicles for gene transfer into murine embryos a 
strong inactivation of the transgene is observed due to de nova methylation during 
embryogenesis (Jahner et al, 1982) although a successful transduction is achieved 
(Jaenisch et al, 1976). SIN vectors lacking the 5’ LTR promoter were shown to overcome 
the CpG methylation in comparison to RVs carrying wildtype 5’ LTR promoter as reported 
for embryonic carcinoma cells (Osborne et al, 1999).  
In the present study, the subzonal virus injection method was used (see also Figure 29). 
Almost 20% of implanted embryos injected with SIN-LVs resulted in born pups by 
applying only 2 subzonal injections. As compared to SIN-LVs injection, only 12% of 
implanted SIN-RVs injected embryos developed to born pups and 9 SIs were performed 
(see also Table 2). Interestingly, 50 % of the born pups were transgenic when using SIN-
LVs, whereas less than 1 % of them were transgenic when applying SIN-RVs (see also 
Figure 31). This extremely low efficiency to generate transgenic mice when using SIN-RV 
might result from low transduction efficiency of SIN-RVs in embryos or the poor survival 
of transgenic mice after birth when SIN-RVs subzonal injection was used.  
 
4.4. Application of LVs in pluripotent stem cells  
In the last decade LVs have been reported as an efficient tool for gene transfer in 
pluripotent stem cells (Hamaguchi et al, 2000; Pfeifer et al, 2002). Moreover, LVs seemed 
to be a favorable vehicle for an efficient production of transgenic mice by implantation of 
LV-transduced pluripotent stem cells in preimplantation embryos (Lois et al, 2002; Okada 
et al, 2007; Rubinson et al, 2003). Chimeric mice that were generated in that way by using 
siRNA expressing LVs showed a strong knockdown of the prion protein, which enabled a 
prolongation of survival of scrapie-infected mice (Pfeifer et al, 2006). Further reports 
demonstrated that lentiviral transduction of somatic cells allowed a successful creation of 
genetically modified disease-specific iPS cells (Lee et al, 2009; Thatava et al, 2011). 
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Additionally, using LV transduction of iPS cells enabled the generation of disease-
corrected, patient-specific haematopietic progenitor cells, which demonstrated its potential 
in cell therapy applications (Raya et al, 2009). Taken together, LVs represent a suitable 
tool for the genetic modification of pluripotent stem cells. As already shown within the 
present study LVs give also rise to be more suitable for use in pluripotent cells as 
compared to e.g. RVs. 
 
4.5. Removal of undifferentiated pluripotent stem cells  
Embryonic as well as induced pluripotent stem cells with their characteristic of 
pluripotency have become promising tools for regenerative medicine since they have been 
isolated (Takahashi et al, 2007b; Wobus & Boheler, 2005). However, there is a potential 
risk of teratoma development if implanted pluripotent stem cell populations are not 
completely differentiated and contaminated with undifferentiated ES or iPS cells (Blum & 
Benvenisty, 2008). Thus, before the technology can be turned into clinical applications, 
this major safety obstacle has to be solved. For minimization of tumorigenesis due to 
undifferentiated pluripotent cells, different approaches have already been developed to 
remove the undifferentiated cells e.g. by using cytotoxic antibodies against undifferentiated 
ES cells (Choo et al, 2008; Tan et al, 2009) or by applying an antibody against a surface 
antigen of ES cells in combination with FACS sorting-based separation (Tang et al, 2011). 
Another method is the use of a suicide strategy based on a TK/GCV system to eliminate 
undifferentiated pluripotent cells (Jung et al, 2007; Naujok et al, 2010; Schuldiner et al, 
2003). The principle of TK/GCV systems is the conversion of the prodrug GCV by the TK 
(thymidine kinase) from Herpes simplex virus leading to a toxic metabolite that eliminates 
TK expressing cells upon GCV treatment. Importantly, the TK/GCV-based treatment has 
already been proven for its general safety in vivo and is already in use in clinical trials for 
cancer therapy (Kubo et al, 2003; Li et al, 2006; Sterman et al, 1998; Wildner et al, 1999). 
Furthermore, it was also stated as a “safety tool” in adaptive immunotherapy (Bonini et al, 
2007; Georgoudaki et al, 2010; Lupo-Stanghellini et al, 2010). 
Genetic modification of ES cell lines to express the HSV-TK gene has already been 
achieved by several groups (Goodwin et al, 2001; Jung et al, 2007; Naujok et al, 2010; 
Schuldiner et al, 2003). Various routes to deliver the transgene have been studied (Jung et 
al, 2007; Schuldiner et al, 2003). In previous studies, TK expression in ES cells was for 
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example achieved by plasmid transfection (Naujok et al, 2010; Schuldiner et al, 2003). 
However, to obtain a stable transgene expression, LVs represent highly efficient vehicles 
for the genetic modification of pluripotent stem cells in vitro as well as in vivo (Pfeifer et al, 
2002). Using ubiquitous promoters like PGK (Schuldiner et al, 2003) or CMV (Jung et al, 
2007) to drive TK expression led to elimination of all transplanted cells (Schuldiner et al, 
2003), whereas using promoter of pluripotency genes for TK expression resulted in the 
death of only undifferentiated ES cells (Naujok et al, 2010). Hence, a combination of LVs 
expressing TK under the control of promoters of pluripotency genes represents a promising 
strategy to achieve a stable and specific elimination of pluripotent stem cells upon GCV 
treatment.  
 
4.6. TK/GCV system in pluripotent stem cells for regenerative medicine 
In the present study, LVs carrying promoters of different pluripotency genes (Nanog, Oct-
3/4, EOS-C3, EOS-S4) were used to establish pluripotent cells stably expressing TK gene. 
In order to minimize the risk of insertional mutagenesis caused by integrating LVs, cells 
transduced at low copy number were investigated that were treated with GCV.  
Preliminary in vitro experiments revealed a high killing effect of LV-transduced ES and 
iPS cells upon GCV treatment using Nanog- and Oct3/4 promoters. However, a complete 
elimination of undifferentiated cells was not achieved (see also Figure 35). An incomplete 
elimination might result from an insufficient TK expression level of transduced cells. 
Therefore, the EOS promoters, that have been proven to achieve higher transgene 
expression in pluripotent stem cells, were used to increase TK expression (Hotta et al, 
2009). Although the EOS-S4 promoter led to the highest TK expression in cells, a much 
higher killing efficiency of undifferentiated cells was still not observed. This suggests that 
survival of undifferentiated cells is more likely the consequence of untransduced cells that 
can not be eliminated upon GCV treatment. To overcome this circumstance, single copy 
LV-transduced ES cell clones were therefore picked and further investigated to ensure TK 
expression in the whole cell populations. Unfortunately, in differentiated single ES cell 
clones (NT #8 and NT #11) more than 1% of Oct-3/4-positive cells (undifferentiated ES 
cells) were still observed upon GCV treatment (see also Figure 47B). This might result 
from a contamination with untransduced cells when picking the single cell clones. The 
problem can be solved through further subcloning to achieve genuine single ES cell clones. 
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This was not performed within the scope of the present work. Another explanation for the 
survival of undifferentiated cells after GCV treatment might be the epigenetic silencing of 
integrated LV provirus in the picked single copy ES cell clones (Hofmann et al, 2006). The 
CpG methylation-related transgene silencing in LV-transduced ES cell clones has already 
been shown in the first part of the work (3.1.2).  
However, neither by raising TK expression using stronger EOS promoters nor by 
analyzing single copy ES cell clones seemed to enable a complete elimination of 
undifferentiated cells upon GCV treatment. Another approach to obtain pure cell 
populations is the use of a pre-selection strategy that was also investigated in the present 
study. This pre-selection method needs neither the additional clonal selection nor a 
screening using Southern blot analysis that is needed for the identification of single copy 
ES cell clones. As pre-selection tool a hygromycin resistance gene was used to select for 
the LV-transduced ES cells. The resistance gene was driven by the ubiquitous promoter 
PKG enabling selection of cells of each differentiation state. The PGK-hygromycin 
cassette was inserted into the LV-construct EOS-S4-TK (ST) resulting in the LV double-
cassette STPH. As expected, STPH-transduced ES cells carrying low copy number of LVs 
without hygromycin selection showed a significant higher but not complete elimination of 
undifferentiated ES cells upon GCV treatment as compared to untransduced cells. 
Importantly, GCV treatment of STPH-transduced ES cells after hygromycin pre-selection 
indeed resulted in a complete elimination of undifferentiated cells in vitro. Finally, these 
pre-selected cell populations were also applied in vivo in a mouse teratoma model. 
Importantly, when applying pre-selected STPH-transduced ES cells with low copy number, 
no teratomas were observed upon GCV administration. In contrast, tumor formation was 
detected when using untransduced ES cells and GCV application or when applying STPH 
transduced ES cells but using saline solution instead of GCV. These teratomas exhibited all 
three germ layers. Similar findings have been also reported in the work of Cheng et al 
(Cheng et al, 2012). They showed that LV-mediated TK expression in ES cells resulted in 
selectively ablation of tumors derived from differentiated cell populations in vivo when 
GCV was applied (Cheng et al, 2012). 
To simplify the manipulation of LV-transduced ES cells, it was furthermore tested if a 
similar killing efficiency can be achieved by avoiding the initial selection at the same time 
using just higher LV doses for ES cell transduction resulting in higher copy number of LVs. 
Thus, STPH-transduced ES cell populations with high copy number of LVs (~4 copies per 
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genome in average) without pre-selection were tested in vitro as well as in vivo. Due to the 
risk of insertional mutagennesis higher LV doses were not applied. Compared to the 
control group, a significant reduction in teratoma weight (around 65%) was observed for 
STPH-transduced ES cells with high copy number without pre-selection when treated with 
GCV. However, the complete absence of teratoma was not achieved. These findings 
suggest that pre-selection of the transduced ES cells is required to achieve complete 
elimination of undifferentiated ES cells using the TK/GCV strategy. This might facilitate 
the development of clinical approaches in regenerative medicine. 
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5. Summary 
Embryonic stem cells are characterized by their self-renewal capability and pluripotency. 
They represent an unlimited cell source for regenerative medicine. In order to genetically 
modify ES cells for gene therapy, self-inactivating lentiviral vectors (SIN-LVs) have been 
proposed as versatile tools for the gene transfer in vitro, ex vivo or in vivo leading to stable 
transgene expression (Matrai et al, 2010; Pfeifer et al, 2002). Although retroviral vectors 
(RVs) were also used for the genetic modifications of ES cells, a major limitation in using 
RVs is the epigenetic silencing (Jahner et al, 1982). However, the performance of SIN-RVs 
as well as SIN-LVs has been reported in HSCs (Schambach et al, 2006a) but not in ES 
cells. Therefore, in the first part of this work the focus lied on the comparison between 
SIN-LV and SIN-RV transduction of ES cells. The data obtained showed a similar 
transgene expression level of both SIN-LVs and SIN-RVs transduced ES cells under 
undifferentiation conditions. Under differentiation conditions transgene silencing in SIN-
LVs as well as SIN-RVs transduced ES cells was observed that mainly was due to CpG 
methylation. For both vectors the contribution of CpG methylation to transgene silencing 
was of the same extent. For a more accurate analysis of SIN-LV- and SIN-RV-mediated 
transgene expression, transduced ES cell clones with either high or low expression level 
were picked for further analysis. In case of SIN-RV ES cell clones, both clones (low and 
high expressing) showed strong transgene silencing under differentiation conditions due to 
CpG methylation. In contrast, only the low expressing SIN-LV ES cell clone showed high 
CpG methylation level under differentiation conditions. Importantly, the high expressing 
LV ES cell clone revealed a lower CpG methylation level and transgene expression was 
still observed under differentiation conditions. Moreover, using subzonal injection for the 
generation of transgenic mice, injection of SIN-LVs in preimplantation embryos resulted in 
around 50 % transgenic mice of born pups whereas SIN-RVs subzonal injections led to 
less than 1 %. This data indicated the successful and efficient usage of SIN-LV 
transduction of murine embryos whereas SIN-RVs showed very low efficient transduction. 
Taken together, SIN-LVs seem to be the proper vehicle for gene transfer either in ES cells 
or in embryos for the generation of transgenic mice. 
 
Using pluripotent stem cell derived cells for regenerative medicine carries the potential risk 
of tumor formation due to the contamination with residual undifferentiated cells (Blum & 
Benvenisty, 2008; Nussbaum et al, 2007; Wakitani et al, 2003). Therefore, the specific 
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elimination of pluripotent stem cells was investigated in the second part of this work. 
Pluripotent stem cells including ES and iPS cells were transduced with LVs carrying 
thymidine kinase (TK) from Herpes simplex virus under control of promoters of 
pluripotency genes. TK expressing cells are in turn sensitive to ganciclovir (GCV) as TK 
converts GCV into a toxic metabolite leading to cell death. Treatment of TK transduced 
pluripotent cells in not further selected (mixed) cell populations with GCV led indeed to a 
high elimination of undifferentiated cells. Although picked single LV-transduced ES cell 
clones showed a higher killing efficiency upon GCV treatment complete elimination of 
undifferentiated cells was not observed. However, raising TK expression by using the 
stronger EOS promoters in mixed ES cell populations did also not result in a significant 
reduction of undifferentiated cells. In order to obtain complete transduced cell populations, 
a pre-selection strategy with hygromycin resistance gene was thus applied. These STPH 
(LV-EOS-S4-TK-PGK-Hygromycin)-transduced ES cell populations carrying only low 
copy number of LVs demonstrated a complete elimination of undifferentiated cells after 
Hygromycin pre-selection upon GCV administration in vitro. More importantly, no 
teratoma was observed when pre-selected cells were injected into mice that were treated 
with GCV. These in vivo data confirmed the in vitro findings and suggested that STPH-
transduced ES cells with pre-selection seemed to be completely eliminated upon GCV 
treatment if they did not undergo differentiation. This gives rise to possible promising 
applications in future clinical approaches. 
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